ANTHOZOA DERIVED CHROMOPHORES/FLUOROPHORES AND METHODS FOR USING THE SAME

Abstract: Anthozoa derived chromo/fluoroproteins and mutants thereof, as well as nucleic acid compositions encoding the same, are provided. Specific proteins of interest include chromo/fluoroproteins from the following specific anthozoa species: Anemonia majano, Clavularia sp., Zoanthus sp., Zoanthus sp., Discosoma striata, Discosoma sp. "red", Anemonia sulcata, Discosoma sp. "green", Discosoma sp. "magenta", and mutants thereof. Also provided are fragments of the subject proteins and nucleic acids encoding the same, as well as antibodies to the subject proteins and transgenic cells and organisms. The subject protein and nucleic acid compositions find use in a variety of different applications. Finally, kits for use in such applications that include the subject proteins are provided.

Description: ANTHOZOA DERIVED CHROMOPHORES/FLUOROPHORES AND METHODS FOR USING THE SAME CROSS REFERENCE TO RELATED APPLICAΗONS This application is a ccmtiπuatiαn-in-part of the followmg applications: application serial no. 09/418,529 filed October 14, 1999; application serial no. 09/418,917 filed October 15, 1999; application serialno. 09/418,922 filed October 15, 1999; application serialno. 09/444,338 filed November 19, 1999; application serial no. 09/444,341 filed November 19, 1999; application serial no. 09/457,556 filed December 9, 1999; application serial no. 09/458,477 filed December 9, 1999; application serial no. 09/458,144 filed December 9, 1999; application serialno. 09/457,898 filed December 9, 1999; as well as application serial no. 60/211,627 filed on June 14, 2000; application serial no. 60/211,687 filed an June 14, 2000; application serialno. 60/211,609 filed on June 14, 2000; application serial no. 60/211,626 filed on June 14, 2000; application serial no. 60/211,880 filed on June 14, 2000; application serial no. 60/211,607 filed on June 14, 2000; application serial no. 60/211,766 filed on June 14, 2000; application serial no. 60/211,888 filed on June 14, 2000; and application serial no.60/212/070 filed on June 14, 2000; the disclosures of which applications are herein incorporated by reference. This application also claims priority to Inteπiatiønal Application Serial No. PCT US99/29405 filed December 10, 1999. INTRODUCTION Field of the Invention The field of this invention is chromoproteins, specifically fluorescent proteins. Background of the Invention Labeling is a tool for marking a protein, cell, or organism of interest and plays a prominent role in many biochemistry, molecular biology and medical diagnostic applications. A variety of different labels have been developed, mchiding radiolabels, chrαmolabels, fluorescent labels, chenmuminescent labels, etc. However, there is continued interest in the development of new labels. Of particular interest is the development of new protein labels, including chrαmo- and fluorescent protein labels. Relevant Literature U.S. Patents of mterest include: 6,066,476; 6,020,192; 5,985,577; 5,976,796; 5,968,750; 5,968,738; 5,958,713; 5,919,445 and 5,874,304. Also of mterest are: Matz, M.V., et al. (1999) Nature Biotechnol, 17:969-973; Living Colors Red Fluorescent Protein (October 1999) CLONTECHniques XTV (4):2-6; Living Colors Enhanced GFP Vectors (April 1996) CLONTECHmques XI(2) 2-3, Haas, J , et al (1996) Curr Biol 6 315-324, Rizzuto, R , et al (1996) Curr Biol 6 183-188, and Kozak, M (1987) Nucleic Acids Res 15 8125-8148, Lukyanov, K , et al (2000) J Biol Chemistry 275(34) 25879-25882 SUMMARY OF THE INVENTION Anthozoa derived chromo/fluoroproteins and mutants thereof, as well as nucleic acid compositions encodmg the same, are provided Specific proteins of mterest mclude chromo/fluoroproteins from the followmg specific anthozoa species Anemoma majano, Clavulaπa sp , Zoanthus sp , Zoanthus sp , Discosoma striata, Discosoma sp "red", Anemoma sulcata, Discosoma sp "green", Discosoma sp "magenta", and mutants thereof Also provided are fragments of the subject protems and nucleic acids encodmg the same, as well as antibodies to the subject protems and transgemc cells and organisms The subject protem and nucleic acid compositions find use m a variety of different applications Finally, kits for use m such applications that mclude the subject protems are provided BREIF DESCRIPTION OF THE FIGURES Figure 1 provides the nucleotide and ammo acid sequence of amFP486 Figure 2 provides the nucleotide and ammo acid sequence of cFP484 Figure 3 provides the nucleotide and ammo acid sequence of zFP506 Figure 4 provides the nucleotide and ammo acid sequence of zFP538 Figure 5 provides the nucleotide and ammo acid sequence of dsFP483 Figure 6 provides the nucleotide and ammo acid sequence of drFP583 Figure 7 provides the nucleotide and ammo acid sequence of asFP600 Figure 8 provides the nucleotide and ammo acid sequence of dgFP512 Figure 9 provides the nucleotide and a mo acid sequence of dmFP592 DEFINITIONS In accordance with the present mvention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art Such techniques are explamed fully m the literature See, e g , Maniatis, Fπtsch & Sambrook, "Molecular Cloning A Laboratory Manual (1982), "DNA Clomng A Practical Approach," Volumes I and II (D N Glover ed 1985), "Ohgonucleotide Synthesis" (M J Gait ed 1984), "Nucleic Acid Hybridization" (B D Hames & S J Higgins eds (1985)), "Transcription and Translation" (B D Hames & S J Higgins eds (1984)), "Animal Cell Culture" (R I Freshney, ed (1986)), "Immobilized Cells and Enzymes" (IRL Press, (1986)), B Perbal, "A Practical Guide To Molecular Clomng" (1984) A "vector" is a rephcon, such as plasmid, phage or cosmid, to which another DNA segment may be attached so as to brmg about the replication of the attached segment A "DNA molecule" refers to the polymeric form of deoxyribonucleotides (adenine, guanine, thymine, or cytosine) in either single stranded form or a double-stranded helix. This term refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, this term includes double-stranded DNA found, inter aha, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. A DNA "coding sequence" is a DNA sequence which is transcribed and translated into a polypeptide in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus. A coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g., mammahan) DNA and synthetic DNA sequences. A polyadenylation signal and transcription termination sequence may be located 3' to the coding sequence. As used herein, the term "hybridization" refers to the process of association of two nucleic acid strands to form an antiparallel duplex stabilized by means of hydrogen bonding between residues of the opposite nucleic acid strands. The term "ohgonucleotide" refers to a short (under 100 bases in length) nucleic acid molecule. "DNA regulatory sequences", as used herein, are transcriptional and translational control sequences, such as promoters, enhancers, polyadenylation signals, terminators, and the like, that provide for and/or regulate expression of a coding sequence in a host cell. A "promoter sequence" is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence. For purposes of defining the present invention, the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background. Within the promoter sequence will be found a transcription initiation site, as well as protein binding domains responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain "TATA" boxes and "CAT" boxes. Various promoters, including inducible promoters, may be used to drive the various vectors of the present invention. As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence. A cell has been "transformed" or "transfected" by exogenous or heterologous DNA when such DNA has been introduced inside the cell. The transforming DNA may or may not be integrated (covalently linked) into the genome of the cell. In prokaryotes, yeast, and mammahan cells for example, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome rephcation. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. A "clone" is a population of cells derived from a single cell or common ancestor by mitosis A "cell Ime" is a clone of a primary cell that is capable of stable growth m vitro for many generations A "heterologous" region of the DNA construct is an identifiable segment of DNA within a larger DNA molecule that is not found in association with the larger molecule in nature Thus, when the heterologous region encodes a mammahan gene, the gene will usually be flanked by DNA that does not flank the mammalian genomic DNA m the genome of the source orgamsm In another example, heterologous DNA mcludes codmg sequence m a construct where portions of genes from two different sources have been brought together so as to produce a fusion protem product Allelic variations or naturally-occurring mutational events do not give rise to a heterologous region of DNA as defined herein As used herein, the term "reporter gene" refers to a codmg sequence attached to heterologous promoter or enhancer elements and whose product may be assayed easily and quantifϊably when the construct is introduced into tissues or cells The ammo acids described herein are preferred to be m the "L" isomeric form The ammo acid sequences are given m one-letter code (A alanine, C cysteme, D aspartic acid, E glutamic acid, F phenvlalanine, G glycine, H histidine, I isoleucine, K lysine, L leucme, M methionine, N asparagine, P prolme, Q glutamine, R arginine, S serme, T threonine, V vahne, W tryptophan, Y tyrosme, X any residue) NH2 refers to the free am o group present at the ammo terminus of a polypeptide COOH refers to the free carboxy group present at the carboxy terminus of a polypeptide In keepmg with standard polypeptide nomenclature, J Biol Chem , 243 (1969), 3552-59 is used The term "lmmunologicalfy active" defines the capability of the natural, recombinant or synthetic chromo/fluorescent protem, or any oligopeptide thereof, to induce a specific immune response m appropriate animals or cells and to bmd with specific antibodies As used herem, "antigemc ammo acid sequence" means an ammo acid sequence that, either alone or m association with a carrier molecule, can ehcit an antibody response in a mammal The term ' specific bmdmg," m the context of antibody bmdmg to an antigen, is a term well understood in the art and refers to bmdmg of an antibody to the antigen to which the antibody was raised, but not other, unrelated antigens As used herem the term "isolated" is meant to describe a polynucleotide, a polypeptide, an antibody, or a host cell that is m an environment different from that in which the polynucleotide, the polypeptide, the antibody, or the host cell naturally occurs DESCRIPTION OF THE SPECIFIC EMBODIMENTS Anthozoa derived chromo/fluoroproteins and mutants thereof, as well as nucleic acid compositions encodmg the same, are provided Specific protems of mterest mclude chromo/fluoroproteins from the followmg specific anthozoa species Anemoma majano, Clavularia sp , Zoanthus sp , Zoanthus sp , Discosoma striata, Discosoma sp "red", Anemoma sulcata, Discosoma sp "green", Discosoma sp "magenta", and mutants thereof Also provided are fragments of the subject protems and nucleic acids encoding the same, as well as antibodies to the subject protems and transgenic cells and organisms The subject protem and nucleic acid compositions find use m a variety of different applications Finally, kits for use in such applications that mclude the subject protems are provided In further descπbmg the subject mvention, the subject nucleic acid compositions will be described first, followed by a discussion of the subject protem compositions, antibody compositions and transgenic cells/organisms Next a review of representative methods in which the subject protems find use is provided Before the subject mvention is further described, it is to be understood that the mvention is not limited to the particular embodiments of the mvention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not mtended to be limiting Instead, the scope of the present mvention will be established by the appended claims In this specification and the appended claims, the singular forms "a," "an," and "the" mclude plural reference unless the context clearly dictates otherwise Unless defined otherwise, all technical and scientific terms used herem have the same meanmg as commonly understood to one of ordmary skill in the art to which this invention belongs NUCLEIC ACID COMPOSITIONS As summarized above, the subject mvention provides nucleic acid compositions encodmg Anthozoa chromo- and fluoroprotems and mutants thereof, as well as fragments and homologues of these protems By nucleic acid composition is meant a composition compnsmg a sequence of DNA havmg an open reading frame that encodes an Anthozoa chromo/fluoro polypeptide of the subject mvention, l e , an Anthozoa chromo/fluoroprotem gene, and is capable, under appropriate conditions, of being expressed as an Anthozoa chromo/fluoro protem accordmg to the subject mvention Also encompassed m this term are nucleic acids that are homologous, substantially similar or identical to the nucleic acids encodmg protems of the present mvention Thus, the subject mvention provides genes and coding sequences thereof encodmg the protems of the subject mvention, as well as homologs thereof The subject nucleic acids are isolated, I e , are present in other than then natural environment Specific nucleic acid compositions of mterest are those that encode chromo/fluoroproteins (and mutants thereof) from the followmg specific anthozoa species Anemoma majano, Clavularia sp , Zoanthus sp , Zoanthus sp , Discosoma striata, Discosoma sp "red", Anemoma sulcata, Discosoma sp "green", Discosoma sp "magenta " Each of these particular types of nucleic acid compositions of mterest is now discussed m greater detail individually Anemonia majano In these embodiments, the nucleic acid compositions are found m, or derived from a nucleic acid found in, an organism from Sub-class Zoantharia, often Order Actimaria, more often Sub-order Endomyaria, usually Family Actiniidae, and more usually Genus Anemoma, where m many embodiments, the organism is Anemoma majano, where the specific prote of mterest from Anemoma majano is amFP486 (1 e , NFP-1), and homologues/mutants, e g , Mutl5, Mut32, thereof are of particular mterest m many embodiments The wild type cDNA codmg sequence for amFP486 is provided m SEQ ID NO 01 Clavularia sp In these embodiments, the nucleic acids are found m or derived from nucleic acids found m orgamsms from Sub-class Alcyonaπa, often Order Stolonifera, and more often the Family Clavulariidae, where the organism is usually from the Genus Clavularia, and m certain embodiments, the organism is Clavularia sp , where the specific fluorescent protem from Clavularia sp is cFP484 (I e , NFP-2), and homologues/mutants, e g , Δ19 cFP484 and Δ38 cFP484, thereof are of particular mterest m many embodiments The wild type cDNA codmg sequence for cFP484 is provided m SEQ ID No 03 Zoanthus sp I In these embodiments, the nucleic acids are found m or derived from nucleic acids found m an orgamsm from Sub-class Zoantharia, often Order Zoanthidea, more often Sub-order Brachycnenua, usually Family Zoanthidae, and more usually Genus Zoanthus, where m certain embodiments, the orgamsm is Zoanthus sp , where the specific fluorescent protem is zFP506 (I e , NFP-3), and homologues/mutants, e g , N65M variant of zFP506, thereof are of particular mterest m many embodiments The wild type cDNA codmg sequence for zFP506 is provided m SEQ ID Nos 05 Zoanthus sp II In these embodiments, the nucleic acids are found in or derived from nucleic acids found m an orgamsm from Sub-class Zoantharia, often Order Zoanthidea, more often Sub-order Brachycnenua, usually Family Zoanthidae, and more usually Genus Zoanthus, where m certain embodiments, the orgamsm is Zoanthus sp , where the specific fluorescent protem is zFP538 (NFP-4), and homologues/mutants, e g , M128 variant of zFP538, thereof are of particular mterest many embodiments The wild type cDNA codmg sequence for zFP538 is provided m SEQ ID NO 07 Discosoma striata In these embodiments, the nucleic acids are found m or derived from a nucleic acid found m an orgamsm from Sub-class Zoantharia, often Order Coralhmopharia, more often Family Discosomatidae, and usually Genus Discosoma, where m certain embodiments, the orgamsm is Discosoma striata, where the specific fluorescent protem is dsFP483 (NFP-5), and homologues/mutants thereof are of particular mterest m many embodiments The wild type cDNA codmg sequence for dsFP483 is provided m SEQ ID NO 09 Discosoma sp "red" In these embodiments, the nucleic acids are found m or derived from nucleic acids found m an orgamsm from Sub-class Zoantharia, often Order Coralhmopharia, more often Family Discosomatidae, and usually Genus Discosoma, where m certam embodiments, the orgamsm is Discosoma sp "red" , where the specific fluorescent protem is drFP583 (NFP-6), and homologues/mutants thereof, e g , E5, E8, E5up, E5down, E57, AG4, AG4H, are of particular mterest in many embodiments The wild type cDNA codmg sequence for drFP583 is provided in SEQ ID NO 11 Anemonia sulcata In these embodiments, the nucleic acid is found m or derived from a nucleic acid found in an orgamsm from Sub-class Zoantharia, often Order Actiniaπa, more often Sub-Order Endomyaria, usually Family Actiiuidae, and more usually Genus Anemoma, e g , where in certam embodiments the orgamsm is Anemonia sulcata, where the specific fluorescent protem asFP600 (NFP-7), and homologues/mutants thereof, e g Mutl, are of particular mterest m many embodiments The wild type cDNA codmg sequence for asFP600 is provided m SEQ ID NO 14 Discosoma sp "green" In these embodiments, the nucleic acid is found m or derived from a nucleic acid found m an orgamsm from Sub-class Zoantharia, often Order Coralhmopharia, more often Family Discosomatidae, and usually Genus Discosoma, where m certam embodiments, the orgamsm is Discosoma sp "green " , where the specific fluorescent protem is dmFP592 (NFP-8), and homologues/mutants thereof are of particular mterest m many embodiments The wild type cDNA codmg sequence for dgFP512 is provided in SEQ ID NO 15 Discosoma sp "magenta" In these embodiments, the nucleic acid is a nucleic acid found m or derived from a nucleic acid found m an orgamsm from Sub-class Zoantharia, often Order Coralhmopharia, more often Family Discosomatidae, and usually Genus Discosomam where m certam embodiments, the orgamsm is Discosoma sp "magenta " , where the specific fluorescent protem is dmFP592 (NFP-9), and homologues/mutants thereof are of particular mterest m many embodiments The wild type cDNA codmg sequence for dmFP592 is provided m SEQ ID NO 17 In addition to the above described specific nucleic acid compositions, also of mterest are homologues of the above sequences With respect to homologues of the subject nucleic acids, the source of homologous genes may be any species of plant or animal In certam embodiments, sequence similarity between homologues is at least about 20%, sometimes at least about 25 %, and may be 30 %, 35%, 40%, 50%, 60%, 70% or higher, mcludmg 75%, 80%, 85%, 90% and 95% or higher Sequence similarity is calculated based on a reference sequence, which may be a subset of a larger sequence, such as a conserved motif, codmg region, flanking region, etc A reference sequence will usually be at least about 18 nt long, more usually at least about 30 nt long, and may extend to the complete sequence that is being compared. Algorithms for sequence analysis are known in the art, such as BLAST, described in Altschul et al. (1990), J. Mol. Biol. 215:403-10 (using default settings, i.e. parameters w=4 and 7=17). The sequences provided herein are essential for recognizing related and homologous nucleic acids in database searches. Of particular interest in certain embodiments are nucleic acids of substantially the same length as the nucleic acid identified as SEQ ID NOS:01 to 17, where by substantially the same length is meant that any difference in length does not exceed about 20 number %, usually does not exceed about 10 number % and more usually does not exceed about 5 number %; and have sequence identity to any of these sequences of at least about 90%, usually at least about 95% and more usually at least about 99% over the entire length of the nucleic acid. In many embodiments, the nucleic acids have a sequence that is substantially similar (i.e. the same as) or identical to the sequences of SEQ ID NOS: 01, 03, 05, 07, 09, 11, 13, 15, oi 17. By substantially similar is meant that sequence identity will generally be at least about 60%, usually at least about 75% and often at least about 80, 85, 90, or even 95%. Nucleic acids encoding mutants of the chromo/fluoroproteins of the invention are also provided. Mutant nucleic acids can be generated by random mutagenesis or targeted mutagenesis, using well-known techniques which are routine in the art. In some embodiments, chromo- or fluorescent proteins encoded by nucleic acids encoding homologues or mutants have the same fluorescent properties as the wild-type fluorescent protein. In other embodiments, homologue or mutant nucleic acids encode chromo- or fluorescent proteins with altered spectral properties, as described in more detail herein. Nucleic acids of the subject invention may be cDNA or genomic DNA or a fragment thereof. In certain embodiments, the nucleic acids of the subject invention include one or more of the open reading frame encoding specific fluorescent proteins and polypeptides, and introns, as well as adjacent 5' and 3' non-coding nucleotide sequences involved in the regulation of expression, up to about 20 kb beyond the coding region, but possibly further in either direction. The subject nucleic acids may be introduced into an appropriate vector for extrachromosomal maintenance or for integration into a host genome, as described in greater detail below. The term "cDNA" as used herein is intended to include all nucleic acids that share the arrangement of sequence elements found in native mature mRNA species, where sequence elements are exons and 5' and 3' non-coding regions. Normally mRNA species have contiguous exons, with the intervening introns, when present, being removed by nuclear RNA splicing, to create a continuous open reading frame encoding the protein. A genomic sequence of interest comprises the nucleic acid present between the initiation codon and the stop codon, as defined in the listed sequences, including all of the introns that are normally present in a native chromosome. It may further include 5' and 3' un-translated regions found in the mature mRNA. It may further include specific transcriptional and translational regulatory sequences, such as promoters, enhancers, etc., including about 1 kb, but possibly more, of flanking genomic DNA at either the 5' or 3' end of the transcribed region. The genomic DNA may be isolated as a fragment of 100 kbp or smaller; and substantially free of flanking chromosomal sequence. The genomic DNA flanking the coding region, either 3' or 5', or internal regulatory sequences as sometimes found in introns, contains sequences required for proper tissue and stage specific expression. The nucleic acid compositions of the subject invention may encode all or a part of the subject chromo- /fluorescent proteins. Double or single stranded fragments may be obtained from the DNA sequence by chemically synthesizing oligonucleotides in accordance with conventional methods, by restriction enzyme digestion, by PCR amplification, etc. For the most part, DNA fragments will be of at least 15 nt, usually at least 18 nt or 25 nt, and may be at least about 50 nt. In some embodiments, the subject nucleic acid molecules may be about 100 nt, about 200 nt, about 300 nt, about 400 nt, about 500 nt, about 600 nt, about 700 nt, or about 720 nt in length. The subject nucleic acids may encode fragments of the subject proteins or the full- length proteins, e.g., the subject nucleic acids may encode polypeptides of about 25 aa, about 50 aa, about 75 aa, about 100 aa, about 125 aa, about 150 aa, about 200 aa, about 210 aa, about 220 aa, about 230 aa, or about 240 aa, up to the entire protein. The subject nucleic acids are isolated and obtained in substantial purity, generally as other than an intact chromosome. Usually, the DNA will be obtained substantially free of other nucleic acid sequences that do not include a nucleic acid of the subject invention or fragment thereof, generally being at least about 50%, usually at least about 90% pure and are typically "recombinant", i.e. flanked by one or more nucleotides with which it is not normally associated on a naturally occurring chromosome. The subject polynucleotides (e.g., a polynucleotide having a sequence of SEQ ID NOS: 01 to 17 etc.), the corresponding cDNA the full-length gene and constructs of the subject polynucleotides are provided. These molecules can be generated synthetically by a number of different protocols known to those of skill in the art. Appropriate polynucleotide constructs are purified using standard recombinant DNA techniques as described in, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., (1989) Cold Spring Harbor Press, Cold Spring Harbor, NY, and under current regulations described in United States Dept. of HHS, National Institute of Health (NIH) Guidelines for Recombinant DNA Research. Also provided are nucleic acids that encode fusion proteins of the subject proteins, or fragments thereof, which are fused to a second protein, e.g., a degradation sequence, a signal peptide, etc. Fusion proteins may comprise a subject polypeptide, or fragment thereof, and a non-anthozoa polypeptide ("the fusion partner") fused in-frame at the N-terminus and/or C-terminus of the subject polypeptide. Fusion partners include, but are not limited to, polypeptides that can bind antibody specific to the fusion partner (e.g., epitope tags); antibodies or binding fragments thereof; polypeptides that provide a catalytic function or induce a cellular response; ligands or receptors or mimetics thereof; and the like. In such fusion proteins, the fusion partner is generally not naturally associated with the subject anthozoa portion of the fusion protein, and is typically not an anthozoa protein or derivative/fragment thereof, i.e., it is not found in Anthozoa species. Also provided are constructs comprising the subject nucleic acids inserted into a vector, where such constructs may be used for a number of different applications, including propagation, protein production, etc. Viral and non-viral vectors may be prepared and used, including plasmids. The choice of vector will depend on the type of cell m which propagation is desired and the purpose of propagation Certam vectors are useful for amplifying and making large amounts of the desired DNA sequence Other vectors are suitable for expression m cells m culture Still other vectors are suitable for transfer and expression m cells m a whole animal or person The choice of appropriate vector is well within the skill of the art Many such vectors are available commercially To prepare the constructs, the partial or full-length polynucleotide is mserted mto a vector typically by means of DNA hgase attachment to a cleaved restriction enzyme site m the vector Alternatively, the desired nucleotide sequence can be mserted by homologous recombmation m vivo Typically this is accomplished by attaching regions of homology to the vector on the flanks of the desired nucleotide sequence Regions of homology are added by ligation of oligonucleotides, or by polymerase chain reaction usmg primers compnsmg both the region of homology and a portion of the desired nucleotide sequence, for example Also provided are expression cassettes or systems that find use m, among other applications, the synthesis of the subject protems For expression, the gene product encoded by a polynucleotide of the mvention is expressed m any convement expression system, mcludmg, for example, bacterial, yeast, insect, amphibian and mammahan systems Suitable vectors and host cells are described m U S Patent No 5,654,173 In the expression vector, a subject polynucleotide, e g , as set forth m SEQ ID NOS 01 to 17, is linked to a regulatory sequence as appropriate to obtain the desired expression properties These regulatory sequences can mclude promoters (attached either at the 5' end of the sense strand or at the 3' end of the antisense strand), enhancers, terminators, operators, repressors, and inducers The promoters can be regulated or constitutive In some situations it may be desirable to use conditionally active promoters, such as tissue- specific or developmental stage-specific promoters These are linked to the desired nucleotide sequence usmg the techniques described above for linkage to vectors Any techniques known m the art can be used In other words, the expression vector will provide a transcriptional and translational initiation region, which may be inducible or constitutive, where the codmg region is operably linked under the transcriptional control of the transcriptional initiation region, and a transcriptional and translational termination region These control regions may be native to the subject species from which the subject nucleic acid is obtained, or may be derived from exogenous sources Expression vectors generally have convement restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences encodmg heterologous protems A selectable marker operative in the expression host may be present Expression vectors may be used for, among other thmgs, the production of fusion protems, as described above Expression cassettes may be prepared compnsmg a transcription initiation region, the gene or fragment thereof, and a transcriptional termination region Of particular mterest is the use of sequences that allow for the expression of functional epitopes or domams, usually at least about 8 ammo acids m length, more usually at least about 15 ammo acids in length, to about 25 ammo acids, and up to the complete open reading frame of the gene After introduction of the DNA, the cells containing the construct may be selected by means of a selectable marker, the cells expanded and then used for expression The above described expression systems may be employed with prokaryotes or eukaryotes in accordance with conventional ways, dependmg upon the purpose for expression For large scale production of the protem, a unicellular orgamsm, such as E coli, B subtihs, S cerevisiae, msect cells in combination with baculovirus vectors, or cells of a higher orgamsm such as vertebrates, e g COS 7 cells, HEK 293, CHO, Xenopus Oocytes, etc , may be used as the expression host cells In some situations, it is desirable to express the gene m eukaryotic cells, where the expressed protem will benefit from native foldmg and post-translational modifications Small peptides can also be synthesized m the laboratory Polypeptides that are subsets of the complete protem sequence may be used to identify and mvestigate parts of the protem important for function Specific expression systems of mterest mclude bacterial, yeast, msect cell and mammahan cell derived expression systems Representative systems from each of these categories is are provided below Bacteria Expression systems in bacteria mclude those described m Chang et al , Nature (1978) 275 615, Goeddel et al , Nature (1979) 281 544, Goeddel et al , Nucleic Acids Res (1980) 8 4057, EP 0 036,776, U S Patent No 4,551,433, DeBoer et al , Proc Natl Acad Sci (USA) (1983) 80 21-25, and Siebenhst et al , Cell (1980) 20 269 Yeast Expression systems m yeast mclude those described m Hinnen et al , Proc Natl Acad Sci (USA) (1978) 75 1929, Ito et al , J Bactenol (1983) 153 163, Kurtz et al , Mol Cell Biol (1986) 6 142, Kunze e/ α/ , J Basic Microbiol (1985) 25 141, Gleeson et al , J Gen Microbiol (1986) 732 3459, Roggenkamp et al , Mol Gen Genet (1986) 202 302, Das et al , J Bactenol (1984) 158 1165, De Louvencourt et al , J Bactenol (1983) 154 737, Van den Berg et al , Bio/Technology (1990) 8 135, Kunze et al , J Basic Microbiol (1985) 25 141, Cregg et al , Mol Cell Biol (1985) 53376, U S Patent Nos 4,837,148 and 4,929,555, Beach and Nurse, Nature (1981) 300706, Davidow et al , Curr Genet (1985) 70380, Gaillardin e/ α/ , Curr Genet (1985) 7049, Ballance e/ α/ , Bi ochem Biophys Res Commun (1983) 772 284-289, Tilburn et al , Gene (1983) 26205-221, Yelton et al , Proc Natl Acad Sci (USA) (1984) 81 1470-1474, Kelly and Hynes, EMBO J (1985) 4 475479, EP 0 244,234, and WO 91/00357 Insect Cells Expression of heterologous genes m msects is accomphshed as described m U S Patent No 4,745,051, Fπesen et al , "The Regulation of Baculovirus Gene Expression", in The Molecular Biology OfBaculoviruses (1986) (W Doerfler, ed ), EP 0 127,839, EP 0 155,476, and Vlak et al , J Gen Virol (1988) 69765-776, Miller et al , Ann Rev Microbiol (1988) 42 177, Carbonell et al , Gene (1988) 73 409, Maeda et al , Nature (1985) 315 592-594, Lebacq-Verheyden et al , Mol Cell Biol (1988) 83129, Smith et al , Proc Natl Acad Sci (USA) (1985) 82 8844, Miyajima et al , Gene (1987) 58 273, and Martm et al , DNA (1988) 799 Numerous baculoviral strains and variants and corresponding permissive insect host cells from hosts are described m Luckow et al , Bio/Technology (1988) 647-55, Miller et al , Generic Engineering (1986) 8 277-279, and Maeda et al , Nature (1985) 315 592-594 Mammahan Cells Mammahan expression is accomphshed as described m Dijkema et al , EMBO J (1985) 4 761, Gorman et al , Proc Natl Acad Sci (USA) (1982) 79 6777, Boshart et al , Cell (1985) 41 521 and U S Patent No 4,399,216 Other features of mammahan expression are facilitated as described m Ham and Wallace, Meth Enz (1979) 58 44, Barnes and Sato, Anal Biochem (1980) 702 255, U S Patent Nos 4,767,704, 4,657,866, 4,927,762, 4,560,655, WO 90/103430, WO 87/00195, and U S RE 30,985 When any of the above host cells, or other appropriate host cells or orgamsms, are used to replicate and/or express the polynucleotides or nucleic acids of the mvention, the resulting replicated nucleic acid, RNA expressed protem or polypeptide, is within the scope of the mvention as a product of the host cell or orgamsm The product is recovered by any appropriate means known m the art Once the gene conespondmg to a selected polynucleotide is identified, its expression can be regulated m the cell to which the gene is native For example, an endogenous gene of a cell can be regulated by an exogenous regulatory sequence mserted mto the genome of the cell at location sufficient to at least enhance expressed of the gene m the cell The regulatory sequence may be designed to integrate mto the genome via homologous recombmation, as disclosed m U S Patent Nos 5,641,670 and 5,733,761, the disclosures of which are herem incorporated by reference, or may be designed to integrate mto the genome via non- homologous recombmation, as described in WO 99/15650, the disclosure of which is herein incorporated by reference As such, also encompassed in the subject mvention is the production of the subject protems without mampulation of the encodmg nucleic acid itself, but mstead through mtegration of a regulatory sequence mto the genome of cell that already mcludes a gene encodmg the desired protem, as described m the above incorporated patent documents Also provided are homologs of the subject nucleic acids Homologs are identified by any of a number of methods A fragment of the provided cDNA may be used as a hybridization probe agamst a cDNA library from the target orgamsm of mterest, where low stringency conditions are used The probe may be a large fragment, or one or more short degenerate primers Nucleic acids havmg sequence similarity are detected by hybridization under low stringency conditions, for example, at 50°C and 6xSSC (0 9 M sodium chlorιde/0 09 M sodium citrate) and remam bound when subjected to washing at 55°C in 1 xSSC (0 15 M sodium chlorιde/0 015 M sodium citrate) Sequence identity may be determined by hybridization under stringent conditions, for example, at 50°C or higher and 0 l SSC (15 mM sodium chloπde/01 5 mM sodium citrate) Nucleic acids havmg a region of substantial identity to the provided sequences, e g allelic variants, genetically altered versions of the gene, etc , bmd to the provided sequences under stringent hybridization conditions By usmg probes, particularly labeled probes of DNA sequences, one can isolate homologous or related genes Also of mterest are promoter elements of the subject genomic sequences, where the sequence of the 5' flankmg region may be utilized for promoter elements, mcludmg enhancer bmdmg sites, e g , that provide for regulation of expression m cells/tissues where the subject protems gene are expressed Also provided are small DNA fragments of the subject nucleic acids, which fragments are useful as primers for PCR, hybridization screening probes, etc Larger DNA fragments, i e , greater than 100 nt are useful for production of the encoded polypeptide, as described m the previous section For use m geometric amplification reactions, such as geometric PCR, a pan: of primers will be used The exact composition of the pnmer sequences is not critical to the mvention, but for most applications the primers will hybridize to the subject sequence under stringent conditions, as known in the art It is preferable to choose a pan of primers that will generate an amplification product of at least about 50 nt, preferably at least about 100 nt Algorithms for the selection of primer sequences are generally known, and are available m commercial software packages Amplification primers hybridize to complementary strands of DNA and will prune towards each other The DNA may also be used to identify expression of the gene m a biological specimen The manner in which one probes cells for the presence of particular nucleotide sequences, as genomic DNA or RNA is well established m the literature Briefly, DNA or mRNA is isolated from a cell sample The mRNA may be amplified by RT-PCR, usmg reverse transcriptase to form a complementary DNA strand, followed by polymerase chain reaction amplification using primers specific for the subject DNA sequences Alternatively, the mRNA sample is separated by gel electrophoresis, transferred to a suitable support, e g nitrocellulose, nylon, etc , and then probed with a fragment of the subject DNA as a probe Other techniques, such as ohgonucleotide hgation assays, in situ hybridizations, and hybridization to DNA probes arrayed on a solid chip may also find use Detection of mRNA hybridizing to the subject sequence is indicative of Anthozoa protem gene expression m the sample The subject nucleic acids, mcludmg flankmg promoter regions and codmg regions, may be mutated m various ways known m the art to generate targeted changes m promoter strength, sequence of the encoded protein, properties of the encoded protein, mcludmg fluorescent properties of the encoded protem, etc The DNA sequence or protem product of such a mutation will usually be substantially similar to the sequences provided herein, e g will differ by at least one nucleotide or ammo acid, respectively, and may differ by at least two but not more than about ten nucleotides or ammo acids The sequence changes may be substitutions, insertions, deletions, or a combination thereof Deletions may further mclude larger changes, such as deletions of a domam or exon, e g of stretches of 10, 20, 50, 75, 100, 150 or more aa residues Techniques for in vitro mutagenesis of cloned genes are known Examples of protocols for site specific mutagenesis may be found m Gustin et al (1993), Bwtechniques 14 22, Barany (1985), Gene 37 111-23, Cohcelh et al (1985), Mol Gen Genet 199 537-9, and Prentiα et al (1984), Gene 29 303-13 Methods for site specific mutagenesis can be found m Sambrook et al , Molecular Cloning A Laboratory Manual, CSH Press 1989, pp 15 3-15 108, Werner et al (1993), Gene 126 35-41, Sayers et al (1992), Bwtechniques 13 592-6, Jones and Winistorfer (1992), Bwtechniques 12 528-30, Barton et al (1990), Nucleic Acids Res 18 7349-55, Marotti and Tomich (1989), Gene Anal Tech 6 67-70, and Zhu (1989), Anal Bwchem 111 120-4 Such mutated nucleic acid derivatives may be used to study structure-function relationships of a particular chromo/ fluorescent protem, or to alter properties of the protem that affect its function or regulation Of particular mterest m many embodiments is the followmg specific mutation protocol, which protocol finds use m mutating chromoproteins mto fluorescent mutants In this protocol , the sequence of the candidate protem is aligned with the ammo acid sequence of Aequorea victoria wild type GFP, according to the protocol reported m Matz et al , "Fluorescent protems from nonbiolummescent Anthozoa species," Nature Biotechnology (October 1999) 17 969 -973 Residue 148 of the chromoprotein is identified and then changed to Ser, e g , by site directed mutagenesis, which results m the production of a fluorescent mutant of the wild type chromoprotein See e g , NFP-7 described below, which wild type protem is a chromoprotein that is mutated mto a fluorescent protem by substitution of Ser for the native Ala residue at position 148 Also of mterest are humamzed versions of the subject nucleic acids As used herem, the term "humanized" refers to changes made to the a nucleic acid sequence to optimize the codons for expression of the protem m human cells (Yang et al , Nucleic Acids Research 24 (1996), 4592-4593) In many embodiments, protems found in bioluminescent species are not mcluded within the scope of the mvention In certam embodiments, the GFP homolog and nucleic acids encodmg the same from Renilla reniformis are not mcluded within the scope of the subject invention PROTEIN/POL YPEPTIDE COMPOSITIONS Also provided by the subject mvention are Anthozoa chromo- and fluorescent protems and mutants thereof, as well as polypeptide compositions related thereto As the subject protems are chromoprotems, they are colored protems, which may be fluorescent, low or non- fluorescent As used herem, the terms chromoprotein and fluorescent protem do not include luciferases, such as Renilla luciferase The term polypeptide composition as used herem refers to both the full-length protem, as well as portions or fragments thereof Also included m this term are variations of the naturally occurring protem, where such variations are homologous or substantially similar to the naturally occurring protein, and mutants of the naturally occurring protems, as described m greater detail below The subject polypeptides are present in other than then natural environment In many embodiments, the subject protems have an absorbance maximum ranging from about 300 to 700, usually from about 350 to 650 and more usually from about 400 to 600 nm Where the subject protems are fluorescent protems, by which is meant that they can be excited at one wavelength of light followmg which they will emit light at another wavelength, the excitation spectra of the subject protems typically ranges from about 300 to 700, usually from about 350 to 650 and more usually from about 400 to 600 nm while the emission spectra of the subject protems typically ranges from about 400 to 800, usually from about 425 to 775 and more usually from about 450 to 750 nm The subject protems generally have a maximum extmction coefficient that ranges from about 10,000 to 50,000 and usually from about 15,000 to 45,000 The subject protems typically range in length from about 150 to 300 and usually from about 200 to 300 ammo acid residues, and generally have a molecular weight ranging from about 15 to 35 kDa, usually from about 17 5 to 32 5 kDa In certam embodiments, the subject protems are bright, where by bright is meant that the chromoprotems and their fluorescent mutants can be detected by common methods (e g , visual screening, spectrophotometry, spectrofluorometry, fluorescent microscopy, by FACS machines, etc ) Fluorescence brightness of particular fluorescent protems is determined by its quantum yield multiplied by maximal extmction coefficient Brightness of a chromoprotems may be expressed by its maximal extinction coefficient In certam embodiments, the subject protems fold rapidly followmg expression m the host cell By rapidly folding is meant that the protems achieve then tertiary structure that gives rise to then chromo- or fluorescent quality m a short period of time In these embodiments, the protems fold m a period of time that generally does not exceed about 3 days, usually does not exceed about 2 days and more usually does not exceed about 1 day Specific protems of mterest are chromo/fluoroproteins (and mutants thereof) from the followmg specific anthozoa species Anemoma majano, Clavularia sp , Zoanthus sp , Zoanthus sp , Discosoma striata, Discosoma sp "red", Anemoma sulcata, Discosoma sp "green", Discosoma sp "magenta " Each of these particular types of polypeptide compositions of mterest is now discussed m greater detail individually Anemonia majano The protems of this embodiment have an absorbance maximum ranging from about 250 to 650, usually from about 400 to 500 and more usually from about 440 to 480 nm while the emission maximum typically ranges from about 270 to 670, usually from about 420 to 520 and more usually from about 460 to 500 nm The subject protems typically range m length from about 200 to 250, usually from about 210 to 240 ammo acid residues, and generally have a molecular weight ranging from about 20 to 30, usually from about 22 50 to 27 50 kDa Of particular interest m many embodiments is amFP486 (NFP-1), which has an ammo acid sequence as shown m SEQ ID NO 02 Also of mterest are mutants of this sequence, e g , Mutl , Mut32, and the like Clavularia sp The protems of this embodiment have an absorbance maximum that typically ranges from about 250 to 650, usually from about 400 to 500 and more usually from about 440 to 480 nm and an emission maximum that typically ranges from about 270 to 670, usually from about 420 to 520 and more usually from about 460 to 500 nm, where the subject prote s typically range m length from about 225 to 300, usually from about 250 to 275 ammo acid residues, and generally have a molecular weight ranging from about 25 to 35, usually from about 27 50 to 32 50 kDa Of particular mterest is the cFP484 protem havmg the sequence shown m SEQ ID NO 04, as well as mutants thereof, e g , Δ19 cFP484 and Δ38 cFP484 (NFP-2), and the like Zoanthus sp l The protems of this embodiment have an absorbance maximum that typically ranges from about 300 to 700, usually from about 450 to 550 and more usually from about 480 to 510 nm and an emission maximum that typically ranges from about 320 to 720, usually from about 470 to 570 and more usually from about 500 to 530 nm The subject protems typically range m length from about 200 to 250, usually from about 220 to 240 ammo acid residues, and generally have a molecular weight rangmg from about 20 to 30, usually from about 22 50 to 27 50 kDa Of particular mterest is the protem zFP506 (NFP-3) which has an ammo acid sequence as shown m SEQ ID NO 06, as well as mutants of this protem, e g , the N65M variant, and the like Zoanthus sp II The protems of this embodiment have an excitation maximum that typically ranges from about 300 to 650, usually from about 475 to 575 and more usually from about 500 to 550 nm and an emission maximum that typically ranges from about 310 to 660, usually from about 485 to 585 and more usually from about 510 to 560 nm The subject protems typically range m length from about 200 to 250, usually from about 220 to 240 ammo acid residues, and generally have a molecular weight rangmg from about 20 to 30, usually from about 22 50 to 27 50 kDa Of particular mterest is the protem sFP538 (NFP-4) which has an ammo acid sequence as shown m SEQ ID NO 08, as well as mutants thereof, e g , the M128 variant, etc Discosoma striata The protems of this embodiment have an excitation maximum that typically ranges from about 240 to 640, usually from about 500 to 600 and more usually from about 530 to 560 nm and an emission maximum that typically ranges from about 280 to 680, usually from about 540 to 640 and more usually from about 570 to 600 nm The subject protems typically range m length from about 200 to 250, usually from about 220 to 240 ammo acid residues, and generally have a molecular weight rangmg from about 20 to 30, usually from about 22 50 to 27 50 kDa Of particular mterest m many embodiments is the protem dsFP483 (NFP-5) which has an ammo acid sequence as shown in SEQ ID NO 10, as well as mutants thereof Discosoma sp "red" The proteins of this embodiment have an absorbance maximum that typically ranges from about 250 to 750, usually from about 500 to 600 and more usually from about 540 to 580 nm and have an emission maximum that typically ranges from about 275 to 775, usually from about 525 to 625 and more usually from about 565 to 605 nm The subject protems typically range m length from about 200 to 250, usually from about 220 to 240 ammo acid residues, and generally have a molecular weight rangmg from about 20 to 30, usually from about 22 50 to 27 50 kDa Of particular mterest is the drFP583 (NFP-6) protem that has an ammo acid sequence as shown in SEQ ID NO 12, as well as mutants thereof, e g , E5, E8, E5up, E5down, E57, AG4, AG4H, etc Anemonia sulcata The proteins of this embodiment have an absorbance maximum that typically ranges from about 370 to 770, usually from about 520 to 620 and more usually from about 560 to 580 nm and an emission maximum that typically ranges from about 395 to 795, usually from about 545 to 645 and more usually from about 585 to 605 nm The subject protems typically range m length from about 200 to 250, usually from about 220 to 240 ammo acid residues, and generally have a molecular weight rangmg from about 20 to 30, usually from about 22 50 to 27 50 kDa Of particular mterest is the asFP600 (NFP-7) protem that has an ammo acid sequence as shown m SEQ ID NO 14, as well as mutants thereof, e g Mutl, etc Discosoma sp "green " The protems of this embodiment have an absorbance maximum that typically ranges from about 300 to 700, usually from about 450 to 650 and more usually from about 490 to 510 nm and an emission maximum that typically ranges from about 310 to 710, usually from about 460 to 660 and more usually from about 500 to 520 nm The subject protems typically range m length from about 200 to 250, usually from about 220 to 240 ammo acid residues, and generally have a molecular weight rangmg from about 20 to 30, usually from about 22 50 to 27 50 kDa Of particular mterest is the dgFP512 protem (NFP-8) protem that has an ammo acid sequence as shown m SEQ ID NO 16, as well as mutants thereof Discosoma sp "magenta " The protems of this embodiment have an absorbance maximum that typically ranges from about 375 to 775, usually from about 525 to 625 and more usually from about 560 to 590 nm and an emission maximum that typically ranges from about 395 to 795, usually from about 545 to 645 and more usually from about 580 to 610 nm The subject protems typically range m length from about 200 to 250, usually from about 220 to 240 ammo acid residues, and generally have a molecular weight rangmg from about 20 to 30, usually from about 22 50 to 27 50 kDa Of particular mterest is the dmFP592 (NFP-9) protem that has an ammo acid sequence as shown m SEQ ID NO 18, as well as mutants thereof Homologs or protems (or fragments thereof) that vary m sequence from the above provided specific ammo acid sequences of the subject mvention, l e , SEQ ID NOS 02 to 18, are also provided By homolog is meant a protem havmg at least about 10%, usually at least about 20 % and more usually at least about 30 %, and m many embodiments at least about 35 %, usually at least about 40% and more usually at least about 60 % ammo acid sequence identity to the protem of the subject mvention, as determined usmg MegAhgn, DNAstar (1998) clustal algorithm as described m D G Higgms and P M Sharp, "Fast and Sensitive multiple Sequence Alignments on a Microcomputer," (1989) CABIOS, 5 151-153 (Parameters used are ktuple 1, gap penalty 3, wmdow, 5 and diagonals saved 5) In many embodiments, homologues of mterest have much higher sequence identify, e g , 65%, 70%, 75%, 80%, 85%, 90% or higher Also provided are protems that are substantially identical to the wild type protem, where by substantially identical is meant that the protem has an ammo acid sequence identity to the sequence of wild type protem of at least about 60%, usually at least about 65% and more usually at least about 70 %, where m some instances the identity may be much higher, e g , 75%, 80%, 85%, 90%, 95% or higher In many embodiments, the subject homologues have structural features found m the above provided specific sequences, where such structural features mclude the β-can fold Protems which are mutants of the above-described naturally occurring protems are also provided Mutants may retain biological properties of the wild-type (e g , naturally occurring) protems, or may have biological properties which differ from the wild-type protems The term "biological property" of the subject protems mcludes, but is not limited to, spectral properties, such as absorbance maximum, emission maximum, maximum extinction coefficient, brightness (e g , as compared to the wild-type protem or another reference protem such as green fluorescent protem from A victoria), and the like, in vivo and/or in vitro stability (e g , half-life), etc Mutants mclude smgle ammo acid changes, deletions of one or more ammo acids, N-terminal truncations, C -terminal truncations, insertions, etc Mutants can be generated usmg standard techniques of molecular biology, e g , random mutagenesis, and targeted mutagenesis Several mutants are described herem Given the guidance provided in the Examples, and usmg standard techniques, those skilled in the art can readily generate a wide variety of additional mutants and test whether a biological property has been altered For example, fluorescence intensity can be measured usmg a spectrophotometer at various excitation wavelengths Those protems of the subject mvention that are naturally occurrmg protems are present m a non- naturally occurrmg envnonment, e g , are separated from then naturally occurrmg environment In certam embodiments, the subject proteins are present m a composition that is enriched for the subject protem as compared to its naturally occurrmg environment For example, purified protem is provided, where by purified is meant that the protem is present m a composition that is substantially free of non- Anthozoa chromo/fluoroprotem derived proteins, where by substantially free is meant that less than 90 %, usually less than 60 % and more usually less than 50 % of the composition is made up of non- Anthozoa derived chromoprotems or mutants thereof The protems of the subject mvention may also be present as an isolate, by which is meant that the protem is substantially free of other protems and other naturally occurrmg biologic molecules, such as ohgosacchandes, polynucleotides and fragments thereof, and the like, where the term "substantially free" m this instance means that less than 70 %, usually less than 60% and more usually less than 50 % of the composition containing the isolated protem is some other naturally occurrmg biological molecule In certam embodiments, the protems are present m substantially pure form, where by "substantially pure form" is meant at least 95%, usually at least 97% and more usually at least 99% pure In addition to the naturally occurrmg protems, polypeptides which vary from the naturally occurrmg proteins, e g , the mutant protems described above, are also provided Generally such polypeptides mclude an ammo acid sequence encoded by an open readmg frame (ORE) of the gene encoding an Anthozoa protem, mcludmg the full length protem and fragments thereof, particularly biologically active fragments and/or fragments corresponding to functional domams, e g , transmembrane domam, and the like, and mcludmg fusions of the subject polypeptides to other protems or parts thereof Fragments of mterest will typically be at least about 10 aa m length, usually at least about 50 aa m length, and may be as long as 300 aa m length or longer, but will usually not exceed about 1000 aa m length, where the fragment will have a stretch of ammo acids that is identical to the subject protem of at least about 10 aa, and usually at least about 15 aa, and m many embodiments at least about 50 aa m length In some embodiments, the subject polypeptides are about 25 aa, about 50 aa, about 75 aa, about 100 aa, about 125 aa, about 150 aa, about 200 aa, about 210 aa, about 220 aa, about 230 aa, or about 240 aa m length, up to the entire protem In some embodiments, a protem fragment retains all or substantially all of a biological property of the wild-type protem The subject protems and polypeptides may be obtained from naturally occurrmg sources or synthetically produced For example, wild type protems may be derived from biological sources which express the proteins, e g , Anthozoa species, such as the specific ones hsted above The subject protems may also be derived from synthetic means, e g by expressmg a recombinant gene or nucleic acid coding sequence encoding the protem of mterest m a suitable host, as described above Any convement protem purification procedures may be employed, where suitable protem purification methodologies are described m Guide to Protem Purification, (Deuthser ed ) (Academic Press, 1990) For example, a lysate may prepared from the original source and purified usmg HPLC, exclusion chromatography, gel electrophoresis, affinity chromatography, ANTIBODY COMPOSITIONS Also provided are antibodies that specifically bmd to the subject fluorescent protems Suitable antibodies are obtamed by immunizing a host animal with peptides compnsmg all or a portion of the subject protem Suitable host animals mclude mouse, rat sheep, goat, hamster, rabbit, etc The origin of the protem immunogen will generally be an Anthozoa species The host animal will generally be a different species than the immunogen, e g , mice, etc The immunogen may comprise the complete protem, or fragments and derivatives thereof Preferred lmmunogens comprise all or a part of the protem, where these residues contain the post-translation modifications found on the native target protem lmmunogens are produced m a variety of ways known m the art, e g , expression of cloned genes usmg conventional recombinant methods, isolation from Anthozoa species, etc For preparation of polyclonal antibodies, the first step is immunization of the host animal with the target protem, where the target protem will preferably be m substantially pure form, compnsmg less than about 1% contaminant The immunogen may comprise the complete target protem, fragments or derivatives thereof To mcrease the immune response of the host annual, the target protem may be combmed with an adjuvant, where suitable adjuvants mclude alum, dextran, sulfate, large polymeric anions, oil & water emulsions, e g Freund's adjuvant, Freund's complete adjuvant, and the like The target protem may also be conjugated to synthetic carrier protems or synthetic antigens A variety of hosts may be immunized to produce the polyclonal antibodies Such hosts mclude rabbits, guinea pigs, rodents, e g mice, rats, sheep, goats, and the like The target protem is administered to the host, usually intradermally, with an initial dosage followed by one or more, usually at least two, additional booster dosages Followmg immunization, the blood from the host will be collected, followed by separation of the serum from the blood cells The Ig present m the resultant antiserum may be further fractionated usmg known methods, such as ammonium salt fractionation, DEAE chromatography, and the like Monoclonal antibodies are produced by conventional techniques Generally, the spleen and/or lymph nodes of an immunized host animal provide a source of plasma cells The plasma cells are immortalized by fusion with myeloma cells to produce hybridoma cells Culture supernatant from mdividual hybridomas is screened usmg standard techniques to identify those producmg antibodies with the desired specificity Suitable animals for production of monoclonal antibodies to the human protem mclude mouse, rat, hamster, etc To raise antibodies against the mouse protein, the animal will generally be a hamster, guinea pig, rabbit, etc The antibody may be purified from the hybridoma cell supernatants or ascites fluid by conventional techniques, e g affinity chromatography usmg protem bound to an insoluble support, protem A sepharose, etc The antibody may be produced as a smgle cham, instead of the normal multimeπc structure Smgle cham antibodies are described Jost et al (1994) J B C 269 26267-73, and others DNA sequences encodmg the variable region of the heavy cham and the variable region of the hght cham are hgated to a spacer encodmg at least about 4 ammo acids of small neutral a mo acids, mcludmg glycme and/or serme The protem encoded by this fusion allows assembly of a functional variable region that retains the specificity and affinity of the original antibody Also of mterest m certam embodiments are humamzed antibodies Methods of humanizing antibodies are known m the art The humanized antibody may be the product of an animal havmg transgenic human lmmunoglobuhn constant region genes (see for example International Patent Applications WO 90/10077 and WO 90/04036) Alternatively, the antibody of mterest may be engmeered by recombinant DNA techniques to substitute the CHI, CH2, CH3, hmge domains, and or the framework domam with the conesponding human sequence (see WO 92/02190) The use of Ig cDN A for construction of chimeπc lmmunoglobuhn genes is known m the art (Liu et al (1987) P N A S 84 3439 and (1987) J Immunol 139 3521) mRNA is isolated from a hybridoma or other cell producmg the antibody and used to produce cDNA The cDN A of mterest may be amplified by the polymerase cham reaction usmg specific primers (U S Patent nos 4,683,195 and 4,683,202) Alternatively, a library is made and screened to isolate the sequence of mterest The DNA sequence encodmg the variable region of the antibody is then fused to human constant region sequences The sequences of human constant regions genes may be found m Kabat et al (1991) Sequences of Protems of Immunological Interest. N I H publication no 91-3242 Human C region genes are readily available from known clones The choice of isotype will be guided by the desired effector functions, such as complement fixation, or activity m antibody- dependent cellular cytotoxicity Preferred isotypes are IgGl, IgG3 and IgG4 Either of the human light cham constant regions, kappa or lambda, may be used The chimeπc, humanized antibody is then expressed by conventional methods Antibody fragments, such as Fv, F(ab') and Fab may be prepared by cleavage of the mtact protem, e g by protease or chemical cleavage Alternatively, a truncated gene is designed For example, a chimeπc gene encodmg a portion of the F(ab') 2 fragment would mclude DNA sequences encoding the CHI domam and hmge region of the H cham, followed by a translational stop codon to yield the truncated molecule Consensus sequences of H and L J regions may be used to design oligonucleotides for use as pnmers to introduce useful restriction sites mto the J region for subsequent linkage of V region segments to human C region segments C region cDNA can be modified by site directed mutagenesis to place a restriction site at the analogous position m the human sequence Expression vectors mclude plasmids, retroviruses, YACs, EBV derived episomes, and the like A convement vector is one that encodes a functionally complete human CH or CL lmmunoglobuhn sequence, with appropriate restriction sites engineered so that any VH or VL sequence can be easily mserted and expressed In such vectors, sphcmg usually occurs between the splice donor site m the mserted J region and the sphce acceptor site precedmg the human C region, and also at the sphce regions that occur within the human CH exons Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions The resultmg chimenc antibody may be jomed to any strong promoter, mcludmg retrovnal LTRs, e g SV-40 early promoter, (Okayama et al (1983) Mol Cell Bio 3 280), Rous sarcoma v is LTR (Gorman et al (1982) P N A S 79 6777), and moloney murine leukemia virus LTR (Grosschedl et al (1985) Cell 41 885), native Ig promoters, etc TRANSGENICS The subject nucleic acids can be used to generate transgemc, non-human plants or animals or site specific gene modifications m cell lines Transgemc cells of the subject mvention mclude on or more nucleic acids according to the subject mvention present as a transgene, where mcluded within this definition are the parent cells transformed to mclude the transgene and the progeny thereof In many embodiments, teh transgemc cells are cells that do not normally harbor or conta a nucleic acid accordmg to the subject mvention In those embodiments where the transgemc cells do naturally contam the subject nucleic acids, the nucleic acid will be present m the cell in a position other than its natural location, l e integrated mto the genomic material of the cell at a non-natural location Transgemc animals may be made through homologous recombmation, where the endogenous locus is altered Alternatively, a nucleic acid construct is randomly integrated mto the genome Vectors for stable mtegration mclude plasmids, retroviruses and other animal viruses, YACs, and the like Transgemc organisms of the subject mvention mclude cells and multicellular organisms, e g , plants and animals, that are endogenous knockouts in which expression of the endogenous gene is at least reduced if not eliminated Transgemc organisms of mterest also mclude cells and multicellular organisms, e g , plants and a mals, in which the protem or variants thereof is expressed m cells or tissues where it is not normally expressed and/or at levels not normally present m such cells or tissues DNA constructs for homologous recombmation will comprise at least a portion of the gene of the subject mvention, wherem the gene has the desned genetic modιfication(s), and mcludes regions of homology to the target locus DNA constructs for random mtegration need not mclude regions of homology to mediate recombmation Convemently, markers for positive and negative selection are mcluded Methods for generating cells havmg targeted gene modifications through homologous recombmation are known m the art For various techniques for transfectmg mammahan cells, see Keown et al (1990), Meth Enzymol 185:527- 537 For embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, e g mouse, rat, guinea pig, etc Such cells are grown on an appropriate fibroblast-feeder layer or grown in the presence of leukemia inhibiting factor (LIF). When ES or embryonic cells have been transformed, they may be used to produce transgenic animals. After transformation, the cells are plated onto a feeder layer in an appropriate medium. Cells containing the construct may be detected by employing a selective medium. After sufficient time for colonies to grow, they are picked and analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo manipulation and blastocyst injection. Blastocysts are obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of pseudopregnant females. Females are then allowed to go to term and the resulting offspring screened for the construct. By providing for a different phenotype of the blastocyst and the genetically modified cells, chimeric progeny can be readily detected. The chimeric animals are screened for the presence of the modified gene and males and females having the modification are mated to produce homozygous progeny. If the gene alterations cause lethality at some point in development, tissues or organs can be maintained as allogeneic or congenic grafts or transplants, or in n vitro culture. The transgenic animals may be any non-human mammal, such as laboratory animals, domestic animals, etc. The transgenic animals may be used in functional studies, drug screening, etc. Representative examples of the use of transgenic animals include those described infra. Transgenic plants may be produced in a similar manner. Methods of preparing transgenic plant cells and plants are described in U.S. Pat. Nos. 5,767,367; 5,750,870; 5,739,409; 5,689,049; 5,689,045; 5,674,731; 5,656,466; 5,633,155; 5,629,470 ; 5,595,896; 5,576,198; 5,538,879; 5,484,956; the disclosures of which are herein incorporated by reference. Methods of producing transgenic plants are also reviewed in Plant Biochemistry and Molecular Biology (eds Lea & Leegood, John Wiley & Sons)(1993) pp 275-295. In brief, a suitable plant cell or tissue is harvested, depending on the nature of the plant species. As such, in certain instances, protoplasts will be isolated, where such protoplasts may be isolated from a variety of different plant tissues, e.g. leaf, hypoctyl, root, etc. For protoplast isolation, the harvested cells are incubated in the presence of cellulases in order to remove the cell wall, where the exact incubation conditions vary depending on the type of plant and/or tissue from which the cell is derived. The resultant protoplasts are then separated from the resultant cellular debris by sieving and centrifugation. Instead of using protoplasts, embryogenic explants comprising somatic cells may be used for preparation of the transgenic host. Following cell or tissue harvesting, exogenous DNA of interest is introduced into the plant cells, where a variety of different techniques are available for such introduction. With isolated protoplasts, the opportunity arise for introduction via DNA-mediated gene transfer protocols, including: incubation of the protoplasts with naked DNA, e.g. plasmids, comprising the exogenous coding sequence of interest in the presence of polyvalent cations, e.g. PEG or PLO; and electroporation of the protoplasts in the presence of naked DNA comprising the exogenous sequence of interest. Protoplasts that have successfully taken up the exogenous DNA are then selected, grown into a callus, and ultimately into a transgenic plant through contact with the appropriate amounts and ratios of stimulatory factors, e.g. auxins and cytokinins. With embryogenic explants, a convenient method of introducing the exogenous DNA in the target somatic cells is through the use of particle acceleration or "gene-gun" protocols. The resultant explants are then allowed to grow into chimera plants, cross-bred and transgenic progeny are obtained. Instead of the naked DNA approaches described above, another convenient method of producing transgemc plants is Agrobacterium mediated transformation. With Agrobacterium mediated transformation, co-integrative or binary vectors comprising the exogenous DNA are prepared and then introduced into an appropriate Agrobacterium strain, e.g. A. tumefaciens. The resultant bacteria are then incubated with prepared protoplasts or tissue explants, e.g. leaf disks, and a callus is produced. The callus is then grown under selective conditions, selected and subjected to growth media to induce root and shoot growth to ultimately produce a transgenic plant. UTILITY The subject chromoprotems and fluorescent mutants thereof find use in a variety of different applications, where the applications necessarily differ depending on whether the protein is a chromoprotein or a fluorescent protein. Representative uses for each of these types of proteins will be described below, where the follow described uses are merely representative and are in no way meant to limit the use of the subject proteins to those described below. Chromoprotems The subject chromoprotems of the present invention find use in a variety of different applications. One apphcation of interest is the use of the subject proteins as coloring agents which are capable of imparting color or pigment to a particular composition of matter. Of particular interest in certain embodiments are non- toxic chromoprotems. The subject chromoprotems may be incorporated into a variety of different compositions of matter, where representative compositions of matter include: food compositions, pharmaceuticals, cosmetics, living organisms, e.g., animals and plants, and the like. Where used as a coloring agent or pigment, a sufficient amount of the chromoprotein is incorporated into the composition of matter to impart the desired color or pigment thereto. The chromoprotein may be incorporated into the composition of matter using any convenient protocol, where the particular protocol employed will necessarily depend, at least in part, on the nature of the composition of matter to be colored. Protocols that may be employed include, but are not limited to: blending, diffusion, friction, spraying, injection, tattooing, and the like. The chromoprotems may also find use as labels in analyte detection assays, e.g., assays for biological analytes of interest. For example, the chromoprotems may be incorporated into adducts with analyte specific antibodies or binding fragments thereof and subsequently employed in nmunoassays for analytes of interest in a complex sample, as described in U.S. Patent No. 4,302,536; the disclosure of which is herein incorporated by reference. Instead of antibodies or binding fragments thereof, the subject chromoprotems or chromogenic fragments thereof may be conjugated to hgands that specifically bind to an analyte of interest, or other moieties, growth factors, hormones, and the like; as is readily apparent to those of skill in the art. In yet other embodiments, the subject chromoprotems may be used as selectable markers m recombmant DNA applications, e g , the production of transgemc cells and orgamsms, as described above As such, one can engmeer a particular transgemc production protocol to employ expression of the subject chromoprotems as a selectable marker, either for a successful or unsuccessful protocol Thus, appearance of uie color of the subject chromoprotein in the phenotype of die transgemc orgamsm produced by a particular process can be used to indicate that the particular orgamsm successfully harbors the transgene of mterest, often integrated m a manner that provides for expression of the transgene m the orgamsm When used a selectable marker, a nucleic acid encodmg for the subject chromoprotein can be employed m the transgemc generation process, where this process is described m greater detail supra Particular transgemc orgamsms of mterest where the subject protems may be employed as selectable markers mclude transgemc plants, animals, bacteria, fungi, and the like In yet other embodiments, the chromoprotems (and fluorescent protems) of the subject mvention find use m sunscreens, as selective filters, etc , m a manner similar to the uses of the protems described m WO 00/46233 Fluorescent Proteins The subject fluorescent protems of the present mvention (as well as other components of the subject mvention described above) find use m a variety of different apphcations, where such apphcations mclude, but are not limited to, the followmg The first application of mterest is the use of the subject proteins m fluorescence resonance energy transfer (FRET) apphcations In these apphcations, the subject protems serve as donor and/or acceptors m combmation with a second fluorescent protem or dye, e g , a fluorescent protem as described m Matz et al , Nature Biotechnology (October 1999) 17 969-973, a green fluorescent protem from Aequona victoria or fluorescent mutant thereof, e g , as described m U S Patent No 6,066,476, 6,020,192, 5,985,577, 5,976,796, 5,968,750, 5,968,738, 5,958,713, 5,919,445, 5,874,304, the disclosures of which are herem incorporated by reference, other fluorescent dyes, e g , coumarin and its derivatives, e g 7- amιno-4-methylcoumarιn, aminocoumaπn, bodipy dyes, such as Bodipy FL, cascade blue, fluorescein and its derivatives, e g fluorescein lsothiocyanate, Oregon green, rhodatmne dyes, e g texas red, tetramethylrhodamme, eosins and erythrosms, cyanine dyes, e g Cy3 and Cy5, macrocychc chelates of lanthanide ions, e g quantum dye, etc , cheimlumescent dyes, e g , luciferases, mcludmg those described m U S Patent Nos 5,843,746, 5,700,673, 5,674,713, 5,618,722, 5,418, 155, 5,330,906, 5,229,285, 5,221,623, 5,182,202, the disclosures of which are herem incorporated by reference Specific examples of where FRET assays employing the subject fluorescent protems may be used mclude, but are not limited to the detection of protem-protem mteractions, e g , mammahan two-hybrid system, transcription factor dimeπzation, membrane protem multimeπzation, multiprotein complex formation, etc , as a biosensor for a number of different events, where a peptide or protem covalently links a FRET fluorescent combmation mcludmg the subject fluorescent protems and the linking peptide or protem is, e g , a protease specific substrate, e g , f or caspase mediated cleavage, a linker that undergoes conformational change upon receiving a signal which mcreases or decreases FRET, e g , PKA regulatory domam (c AMP -sensor), phosphorylation, e g , where there is a phosphorylation site m the linker or the linker has bmdmg specificity to phosphorylated/dephosphorylated domam of another protem, or the linker has Ca 2+ bmdmg domam Representative fluorescence resonance energy transfer or FRET applications m which the subject protems find use mclude, but are not limited to, those described m U S Patent Nos 6,008,373, 5,998,146, 5,981,200, 5,945,526, 5,945,283, 5,911,952, 5,869,255, 5,866,336, 5,863,727, 5,728,528, 5,707,804, 5,688,648, 5,439,797, the disclosures of which are herem incorporated by reference The subject fluorescent protems also find use as biosensors m prokaryotic and eukaryotic cells, e g as Ca 2+ ion mdicator, as pH mdicator, as phorphorylation mdicator, as an mdicator of other ions, e g , magnesium, sodium, potassium, chloride and hahdes For example, for detection of Ca ion, protems contammg an EF-hand motif are known to translocate from the cytosol to membranes upon Ca 2+ bmdmg These proteins contam a myπstoyl group that is burned withm the molecule by hydrophobic mteractions with other regions of the protem Bmdmg of Ca + mduces a conformational change exposmg the mynstoyl group which then is available for the insertion mto the hpid bilayer (called a "Ca 2+ -mynstoyl switch") Fusion of such a EF-hand contammg protein to Fluorescent Protems (FP) could make it an mdicator of intracellular Ca 2+ by momtormg the translocation from the cytosol to the plasma membrane by confocal microscopy EF- hand protems suitable for use m this system mclude, but are not limited to recoverm (1-3), calcmeurm B, tropomn C, visinin, neurocalcm, calmoduhn, parvalbumin, and the like For pH, a system based on hisactophihns may be employed Hisactophihns are mynstoylated histidme-rich protems known to exist m Dictyostehum Their bmdmg to actin and acidic hpids is sharply pH-dependent within the range of cytoplasmic pH variations In living cells membrane bmdmg seems to ovemde the interaction of hisactophihns with actin filaments At pH<6 5 they locate to the plasma membrane and nucleus In contrast, at pH 7 5 they evenly distribute throughout the cytoplasmic space This change of distribution is reversible and is attributed to histidme clusters exposed m loops on the surface of the molecule The reversion of intracellular distribution m the range of cytoplasmic pH variations is m accord with a pK of 6 5 of histidme residues The cellular distribution is mdependent of myπstoylation of the protem By fusing FPs (Fluoresent Protems) to msactophihn the intracellular distribution of the fusion protem can be followed by laser scanning, confocal microscopy or standard fluorescence microscopy Quantitative fluorescence analysis can be done by performing Ime scans through cells (laser scanning confocal microscopy) or other electronic data analysis (e g , usmg metamorph software (Umversal Imagmg Corp) and averagmg of data collected m a population of cells Substantial pH-dependent redistribution of hisactophihn-FP from the cytosol to the plasma membrane occurs within 1-2 mm and reaches a steady state level after 5-10 mm The reverse reaction takes place on a similar time scale As such, hisactophihn-fluorescent protem fusion protem that acts m an analogous fashion can be used to momtor cytosohc pH changes m real time m hve mammahan cells Such methods have use m high throuhgput apphcations, e g , m the measurement of pH changes as consequence of growth factor receptor activation (e g epithelial or platelet-derived growth factor) chemotactic stimulation/ cell locomotion, m the detection of intracellular pH changes as second messenger, m the momtormg of mtracellular pH m pH manipulating experiments, and the like. For detection of PKC activity, the reporter system exploits the fact that a molecule called MARCKS (myristoylated alanine-rich C kinase substrate) is a PKC substrate. It is anchored to the plasma membrane via myristoylation and a stretch of positively charged amino acids (ED- domain) that bind to the negatively charged plasma membrane via electrostatic interactions. Upon PKC activation the ED-domain becomes phosphorylated by PKC, thereby becoming negatively charged, and as a consequence of electrostatic repulsion MARCKS translocates from the plasma membrane to the cytoplasm (called the "myristoyl-electrostatic switch"). Fusion of the N-terminus of MARCKS ranging from the myristoylation motif to the ED-domain of MARCKS to fluorescent proteins of the present invention makes the above a detector system for PKC activity. When phosphorylated by PKC, the fusion protein translocates from the plasma membrane to the cytosol. This tianslocation is followed by standard fluorescence microscopy or confocal microscopy e.g. using the Cellomics technology or other High Content Screening systems (e.g. Universal Imaging Corp./Becton Dickinson). The above reporter system has application in High Content Screening, e.g., screening for PKC inhibitors, and as an indicator for PKC activity in many screening scenarios for potential reagents interfering with this signal transduction pathway. Methods of using fluorescent proteins as biosensors also include those described in U.S. Patent Nos. 972,638; 5,824,485 and 5,650,135 (as well as the references cited therein) the disclosures of which are herein incorporated by reference. The subject fluorescent proteins also find use in applications involving the automated screening of arrays of cells expressing fluorescent reporting groups by using microscopic imaging and electronic analysis. Screening can be used for drug discovery and in the field of functional genomics: e. g., where the subject proteins are used as markers of whole cells to detect changes in multicellular reorganization and migration, e.g., formation of multicellular tubules (blood vessel formation) by endothelial cells, migration of cells through Fluoroblok Insert System (Becton Dickinson Co.), wound healing, neurite outgrowth, etc.; where the proteins are used as markers fused to peptides (e.g., targeting sequences) and proteins that allow the detection of change of intracellular location as indicator for cellular activity, for example: signal transduction, such as kinase and transcription factor tianslocation upon stimuli, such as protein kinase C, protein kinase A, transcription factor NFkB, and NFAT; cell cycle proteins, such as cyclin A, cyclin Bl and cyclinE; protease cleavage with subsequent movement of cleaved substrate, phospholipids, with markers for intracellular structures such as endoplasmic reticulum, Golgi apparatus, mitochondria, peroxisomes, nucleus, nucleoli, plasma membrane, histones, endosomes, lysosomes, microtubules, actin) as tools for High Content Screening: co-localization of other fluorescent fusion proteins with these localization markers as indicators of movements of intracellular fluorescent fusion proteins/peptides or as marker alone; and the like. Examples of apphcations involving the automated screening of arrays of cells in which the subject fluorescent proteins find use include: U.S. Patent No. 5,989,835; as well as WO/0017624; WO 00/26408; WO 00/17643; and WO 00/03246; the disclosures of which are herein incorporated by reference. The subject fluorescent proteins also find use in high through-put screening assays. The subject fluorescent proteins are stable proteins with half-lives of more than 24h. Also provided are destabilized versions of the subject fluorescent proteins with shorter half-lives that can be used as transcription reporters for drug discovery. For example, a protein according to the subject invention can be fused with a putative proteolytic signal sequence derived from a protein with shorter half-life, e.g., PEST sequence from the mouse ornithine decarboxylase gene, mouse cyclin Bl destruction box and ubiquitin, etc. Promoters in signal transduction pathways can be detected using destabilized versions of the subject fluorescent proteins for drug screening, e.g., API, NFAT, NFkB, Smad, ST AT, p53, E2F, Rb, myc, CRE, ER, GR and TRE, and the like. The subject proteins can be used as second messenger detectors, e.g., by fusing the subject proteins to specific domains: e.g., PKCgamma Ca binding domain, PKCgamma DAG binding domain, SH2 domain and SH3 domain, etc. Secreted forms of the subject proteins can be prepared, e.g. by fusing secreted leading sequences to the subject proteins to construct secreted forms of the subject proteins, which in turn can be used in a variety of different applications. The subject proteins also find use in fluorescence activated cell sorting apphcations. In such apphcations, the subject fluorescent protein is used as a label to mark a population of cells and the resulting labeled population of cells is then sorted with a fluorescent activated cell sorting device, as is known in the art. FACS methods are described in U.S. Patent Nos. 5,968,738 and 5,804,387; the disclosures of which are herein incorporated by reference. The subject proteins also find use as in vivo marker in animals (e.g., transgenic animals). For example, expression of the subject protein can be driven by tissue specific promoters, where such methods find use in research for gene therapy, e.g., testing efficiency of transgenic expression, among other apphcations. A representative apphcation of fluorescent proteins in transgenic animals that illustrates this class of apphcations of the subject proteins is found in WO 00/02997, the disclosure of which is herein incorporated by reference. Additional apphcations of the subject proteins include: as markers following injection into cells or animals and in cahbration for quantitative measurements (fluorescence and protein); as markers or reporters in oxygen biosensor devices for monotoring cell viability; as markers or labels for animals, pets, toys, food, etc.; and the like. The subject fluorescent proteins also find use in protease cleavage assays. For example, cleavage inactivated fluorescence assays can be developed using the subject proteins, where the subject proteins are engineered to include a protease specific cleavage sequence without destroying the fluorescent character of the protein. Upon cleavage of the fluorescent protein by an activated protease fluorescence would sharply decrease due to the destruction of a functional chromophor. Alternatively, cleavage activated fluorescence can be developed using the subject proteins, where the subject proteins are engineered to contain an additional spacer sequence in close proximity/or inside the chromophor. This variant would be significantly decreased in its fluorescent activity, because parts of the functional chromophor would be divided by the spacer. The spacer would be framed by two identical protease specific cleavage sites. Upon cleavage via the activated protease the spacer would be cut out and the two residual "subunits" of the fluorescent protein would be able to reassemble to generate a functional fluorescent protein. Both of the above types of application could be developed in assays for a variety of different types of proteases, e.g., caspases, etc. The subject proteins can also be used is assays to determine the phosphohpid composition in biological membranes. For example, fusion proteins of the subject proteins (or any other kind of covalent or non-covalent modification of the subject proteins) that allows binding to specific phospholipids to locahze/visuahze patterns of phosphohpid distribution in biological membranes also allowing colocahzation of membrane proteins in specific phosphohpid rafts can be accomphshed with the subject proteins. For example, the PH domain of GRP1 has a high affinity to phosphatidyl-inositol tri-phosphate (PIP3) but not to PIP2. As such, a fusion protein between the PH domain of GRP1 and the subject proteins can be constructed to specifically label PIP3 rich areas in biological membranes. Yet another apphcation of the subject proteins is as a fluorescent timer, in which the switch of one fluorescent color to another (e.g. green to red) concomitant with the ageing of the fluorescent protein is used to determine the activation/deactivation of gene expression, e.g., developmental gene expression, cell cycle dependent gene expression, circadian rhythm specific gene expression, and the like The antibodies of the subject invention, described above, also find use in a number of apphcations, including the differentiation of the subject proteins from other fluorescent proteins. KITS Also provided by the subject invention are kits for use in practicing one or more of the above described apphcations, where the subject kits include a chromo- or fluorescent protein according to the subject methods or a means for making the protein, e.g., a construct comprising a vector that includes a coding region for the subject protein. The protein or construct therefore is present in a suitable storage medium, e.g., buffered solution, typically in a suitable container. Also present in the subject kits may be antibodies to the provided protein. In certain embodiments, the kit comprises a plurahty of different vectors each encoding the subject protein, where the vectors are designed for expression in different environments and/or under different conditions, e.g., constitutive expression where the vector includes a strong promoter for expression in mammalian cells, a promoterless vector with a multiple cloning site for custom insertion of a promoter and tailored expression, etc. The following examples are offered by way of illustration and not by way of limitation. EXPERIMENTAL I. Wild-Type Anthozoa Proteins The following table summarizes the properties of nine specific wild type anthozoa proteins of the subject invention: TABLE I *relative quantum yield was determined as compared to the quantum yield of A victoria GFP **relatιve brightness is extinction coefficient multiphed by quantum yield divided by the same value for A victoria GFP II amFP486 Characterization and Mutants Thereof A Construction of amFP486 Mutants Two mutants of amFP486 were generated, Mutl5 and Mut32 Compared with wildtype amFP486, Mutl5 has the followmg pomt mutations A to G at position 101 (numbered from begmnmg of ATG), T to C at position 129, AAA to TTG at positions 202-204, C to T at position 240 Mut32 has two ammo acid substitutions relative to the wildtype, I e , Asn-34 to Ser, and Lys-68 to met Table 2 hsts the spectral properties of Mutl5 and Mut32 TABLE 2 Spectral Properties of the Isolated Mutl5 and Mut32 *relative brightness is extinction coefficient multiphed by quantum yield divided by the same value for A victoria GFP B Construction and Functional Analysis of Vectors Mut32 DNA was amplified via PCR and reconstructed to EGFP-N1 backbone with BamHI and Notl restriction enzyme sites This vector has the same multiple clomng sites as EGFP-N1 Functional tests of the generated vectors was performed by transient transfection in 293 cells. After 24-hour expression, brighter fluorescent intensity and less photobleaching of pCNFPMut32-Nl were observed by microscopy when compared with pECFP-Nl side by side. Mut32 has fast folding and bright fluorescent intensity, which makes it useful for number of apphcations. Some fusion proteins were tested, such as PKC-gamma-CNFP. PKC was observed to translocate from cytosol to the plasma membrane when cells were treated with PMA (phorbol 12-myristate 13-acetate). C. Generation of Destabilized amFP486 Vectors as Transcription Reporters Three destabilized amFP486 vectors were constructed by fusing different mouse ODC degradation domains such as dl, d2 and d376 to the C-terminal of wild type amFP486. The vectors were constructed in EGFP-N1 backbone. Vectors of pCRE-dlCNFP and ρNF-κB-dlCNFP were constructed by placing dlCNFP downstream of cAMP response element (CRE) or NF-κB response element, respectively. Expression of dlCNFP is up- regulated upon activation of these response elements. D. Functional Analysis of Destabilized amFP486 Functional tests of the destabilized amFP486 were performed by transient transfection in 293 cells. After 24-hour expression, the fluorescent intensity was decreased gradually from d2, dl and d376 because of the fusion with different mouse ODC degradation domains. After 4-hour treatment with protein synthesis inhibitor cycloheximide, d2 fluorescent intensity did not change very much; however, dl fluorescent intensity decreased further 50% of its original intensity. The half-life of dl is around 4 hours. MODCdl is a valuable tool for apphcation as a transcription reporter. However, compared with EGFP-dl (1-hour half-life), pCNFP -MODCdl half-life (4 hours) is still long, so further mutagenesis for MODC degradation domain is still needed for shorter half-life version. Functional tests of vectors pCRE-dlCNFP and pNF-κB-dlCNFP were performed by transient transfection in HEK 293 cells. 16 hours post transfection, 10 μm forskolin was added to induce CRE and 100 ng/ml TNF-alpha was added to induce NF- B for 6 hours. Expression of dlCNFP was analysed using FACS Cahbur. Up to 7 fold increase of fluorescence in forskolin induced CRE activation and 4 fold increase of fluorescence in TNF-alpha induced NF-KB activation was observed (data not shown). E. Construction and Functional Test for Humanized Mut32 (phCNFP-Nl) Since mammahan expression is a very popular tool, human favored codon version is needed for better expression in mammalian cells. To generate humanized Mut32, the Mut 32 sequence was first changed to human favored codon and 23 ohgos (12F and 1 IR) were designed. Next, four rounds of PCR amplification were performed, each round for 20 cycles. PCR cycle was designed as follows: 94°C for 1 min; 94°C for 1 min; 40°C for 1 min; and 72°C for 1 min. The four rounds were: for 1 st round, mixing 2 μl each of every 4 ohgos (60 bp), 5 μl buffer, 1 μl pfu, 1 μl dNTP to make total volume of 50 μl After 20 cycles of PCR, 5 sets of 150 bp and 1 set of 4 last ohgos of 90 bp products were obtamed For 2 nd round, mixing new crude PCR products 10 μl each, 5 μl buffer, 1 μl pfu, 1 μl dNTP to make total volume of 50 μl After 20 cycles of PCR, 2 sets of 270 bp and 1 set of 210 bp PCR products were obtamed For 3 rd round, mixing new crude PCR products After 20 cycles of PCR, 1 set of 510 bp and 1 set of 450 bp products were obtamed For 4 th round, mixing new crude products After 20 cycles of PCR, final PCR product (690 bp) was obtamed Further PCR amplification was performed usmg IF and 1 IR primers As a result, humanized Mut32 was generated This humanized Mut32 was constituted mto EGFP-N1 backbone F Expression of Wildtype and Mutant amFP486 m Mammahan Cells The oπgmal plasmid amFP486 DNAs (wildtype, Mutl5 and Mut32 m pQE30) were used to construct NI version of amFP486 wildtype, Mutl5 and Mut32 as described above The DNAs were mserted mto E coli DH5α HEK 293 cells were transferred with each of the three NI constructs usmg Calcium Phosphate method (Clontech product #K2051-1) The fluorescent mtensity of the transfected cells was analyzed on FACS usmg FL1 (510/30) detectmg channel Five samples were analyzed m parallel for each construct The observed mean value of FL1 fluorescent mtensity of the Ml population of each sample is summarized m Table 3 It shows that the average of the mean value of each construct (Wildtype, Mutl5, and Mut32) has no significant difference TABLE 3 FL1 Fluorescent Intensity of Ml Populatioi 1 Sample # Wildtype Mutl5 Mut32 1 82 84 106 95 84 51 2 77 52 108 73 91 41 3 111 85 97 08 91 30 4 113 06 90 16 98 16 5 104 95 86 34 111 44 Mean 98 04 97 85 95 36 G Generation and Expression of Fusion Protem Mut 15 -mdm2 The Mutl5-mdm2 fusion was generated by the followmg steps first, mdm2 DNA was obtamed by amplifying human Marathon cDNA library (Burke's Lymphoma) usmg primers ATGTGCAATACCAACATGTCTGTACC (SEQ ID No 19) and CTAGGGGAAATAAGTTAGCAC (SEQ ID No 20), secondly, the purified PCR product was then amplified with primers GGAATTCCAGCCATGGTGTGCAATACCAACATGTCTGTACC (SEQ ID No 21) and TCCCCCGGGGGGAAATAAGTTAGCAC (SEQ ID No 22) m order to add Kozac sequence and restriction sites, thirdly, the purified PCR product from step 2 was digested with EcoR I and Sma I and mserted mto EcoR I and Smal of NFP 1 Mut 15 -NI vector (this vector was generated using BamH I and Not I sites of the pEGFP-Nl backbone). The generated Mutl5-mdm2 fusion was then expressed in HEK293 cells. H. Comparison of the Protein Fluorescent Intensity PQE30 amFP486 wildtype, Mutl5 and Mut32 were transformed into DH5α. The bacteria grew in the presence of 1 mM IPTG overnight to induce the protein expression. Cells were lysed in 100 mM Tris, pH8.0 by sonication. Cell lysate was collected after centrifuge at 3000 rpm for 15 minutes at room temperature. The proteins were purified with TALON Metal Affinity Resin. Briefly, after the protein was absorbed on the resin, the beads were washed in stepwise with first wash, then first elution (50 mM imidazole) and second elution (200 mM imidazole) in 100 mM Tris-HCl, pH 8.0. The protein is found mostly in the second step elution. It was found that Mut32 has the highest bacterial expression level, while Mutl5 has the lowest. Samples of each elution fraction were run on SDS-PAGE to check the purity of the proteins. Both wildtype amFP486 and Mut32 show a single band, while Mutl5 has two more minor bands with higher molecular weight (data not shown). The protein concentration (fractionII-2) was checked and measured by Bradford assay (Bio-Rad standard assay) using BSA as a standard. The spectra are shown in Figures 8-11. The fluorescence intensity (fraction II-2) was determined with LS50B Luminescence Spectrometer LS50B. EX = 458 nm, EM = 492 nm, both slits = 2.5 nm. Table 4 shows the protein concentration, relative fluorescent (FL) intensity and intensity/μg protein in 700 μl volume. It shows that Mut32 is as bright as wildtype, while Mutl5 is worse than the wildtype. TABLE 4 Protein Relative FL Intensity/μg Protein Concentration Intensity in 700 μl Volume Wildtype II-2 1.26 μg/5 μl 37.805/5 μl 30.00 Mutl5II-2 0.64 μg/5 μl 10.152/5 μl 15.86 Mut32II-2 6.17 μg/5 μl 186.474/5 μl 30.22 III. Characterization of cFP484 and mutants thereof A. Mutant Generation Two deletion mutants were generated by two separate PCR reactions: Δ19 cFP484 lacks the N- terminal first 19 amino acids of cFP484, and Δ38 cFP484 lacks the N-terminal first 38 amino acids of cFP484. Mammahan expression vectors containing the DNA encoding the fluorescent protein Δ19 cFP484 or Δ38 cFP484 are generated, which are named as ρΔ19 NFP2-N1 and pΔ38 NFP2-N1, respectively. B. Transient Expression of Deletion Mutants of cFP484 in Mammahan Cells HeLa cells were transiently transfected with mammahan expression vector pΔ19 NFP2-N1 which contains the DNA encoding the fluorescent protein Δ19 cFP484. After transfection, cells were incubated for 48 hours at 37°C then fixed m 3 7% formaldehyde Cells were mounted m mounting medium and observed by fluorescence microscopy Digital images were taken with MetaMorph software (Universal Imagmg Corp ) usmg a monochrome cooled CCD camera (Roper Scientific) The filter set XF 114 (Omega Optical) was used to visualize fluorescence emitted by Δ19 cFP484 The image was pseudocolored Δ38 cFP484 is also fluorescent when expressed m HeLa cells IV Characterization of zFP506 and Mutants thereof A Mutant generation One mutant of zFP506 was generated, N65M Compared with wild type zFP506, N65M has the mutation of from "AAC" to "ATG" which results m the conespondmg ammo acid change from Asparagme (N) to Methionine (M) at the position of 65 The spectral properties of N65M are hsted in Table 5 TABLE 5 Spectral Properties of the Isolated N65M *relative brightness is extmction coefficient multiphed by quantum yield divided by the same value for A victoria GFP B Construction and Functional Analysis of Vectors Non-humanized zFP506 DNA was amplified via PCR and reconstructed mto EGFP-N1 backbone This vector has the same multiple clomng sites as EGFP-N1 Functional test of the generated vector was performed by transient transfection m 293 cells 24 hours post transfection, expression of zFP506 was exammed under fluorescent microscope zFP506 showed good fluorescent mtensity and comparable to EGFP-N1 C Generation of Destabilized zFP506 Vectors as Transcription Reporters Smce zFP506 is very stable, it is necessary to generate destabilized versions of zFP506 m order to observe the rapid turnover of the protem By usmg the same technology for destabilized EGFP, two destabilized zFP506 vectors were constructed by fusing mouse ODC degredation domam to the C-terminal of zFP506 The dl version of destabhzed zFP506 has three E to A mutations within MODC degredation domam comparmg to d2 version, therefore result m a shorter half-hfe of the protem to which MODC degradation domam fused to Destabhzed dlzFP506 and d2zFP506 were constructed m EGFP-N1 backbone D Functional Analysis of Destabilized zFP506 Wildtype dlzFP506 was transiently transfected mto 293 cells 24 hours after transfection, CHX was added to stop protem synthesis After 4 hour treatment, cells were exammed under fluorescent microscope It shows that fusion of MODC domam to the zFP506 slightly decreases the fluorescent mtensity compared to zFP506 itself After 4 hour treatment, there is 50% fluorescent mtensity decrease E Application of Destabilized dlzFP506 as Transcription Reporters Destabilized dlzFP506 was constructed mto pCRE-dlGNFP and pNF-κB-dlGNFP vectors Its expression was regulated under cAMP response element (CRE) or NF-κB response element, respectively These vectors were transiently transfected mto 293 cells, and 24 hours post transfection, the expression of dlGNFP was mduced by Forskolm or TNF-α 6 hours after induction, uie culture was analysed by FACS CRE-dlGNFP showed 7 fold of mduction m fluorescence mtensity, while 4 fold of induction was obtamed m NF-i B-dlGNFP (data not shown) This demonstrated that the destabihzed form of GNFP is apphcable as transcription reporters F Construction and Functional Test for Humanized zFP506 and Humanized N65M Smce mammahan expression is a very popular tool, human favored codon version is needed for better expression m mammalian cells Each piece of human favored codon ohgos was linked to form the full length of wild type and/or mutant zFP506 (hGNFP-zFP506, hGNFP-N65M This humanized zFP506 was constituted mto EGFP-Nl backbone V Characterization of zFP538 and mutants thereof One mutant of zFP538 was generated, M128V M128V was generated by introducing a wrong nucleotide m PCR durmg site-specific mutagenesis at position 65 One bright yellow colony was obtamed, and the sequence of this clone was performed It showed that this clone contamed wild type ammo acid Lysme (K) at position 65, but had a substitution from Methiomne (M) to Vahne (V) at position 128 (numbering according to GFP) Further investigations showed that M128V has spectral characteristics very similar to wild type protem zFP538 but folds much faster Table 6 hsts the spectral properties of M128V TABLE 6 Spectral Properties of the Isolated Ml 28V Species NFP Absorbance Emission Maximum Quantum Relative Name Maximum Maximum Extinction Yield Brightness nm nm Coeff Zoanthus sp M128V 531 540 25,360 0 43 0 50 Relative brightness is extinction coefficient multiphed by quantum yield divided by the same value for A victoria GFP A Construction and Functional Analysis of Vectors Both wildtype (wt) and mutant zFP538 DNA were amplified via PCR and reconstructed to EGFP-Nl backbone This vector has the same multiple clomng sites as EGFP-Nl Both pYNFPwt and pYNFPW128V keep the same multiple clomng sites as EGFP-Nl Functional test of the generated vectors was performed by transient transfection m 293 cells After 24-hour expression, pYNFPwt, pYNFPM 12V and EYFP were compared side by side pYNFPwt showed less fluorescent mtensity than EYFP (data not shown), however, pYNFPM 128V showed as bright fluorescent mtensity as EYFP by fluorescent microscopy B Generation of Destabilized zFP538 Vectors as Transcription Reporters By usmg the same technology for destabilized EGFP, destabihzed zFP538 vectors were constructed by fusing different mouse ODC degradation domams such as dl and d2 to the C-terminal of zFP538 The dl version of destabilized YNFP has three E to A mutations within MODC degradation domam compared to d2 version Vectors pYNFPM 128 V-MODCdl and pYNFPM 128V-MODCd2 were constructed m EGFP-N 1 backbone C Functional Analysis of Destabilized zFP538 Functional test of the destabilized zFP538 was performed by transient transfection m 293 cells After 24-hour expression, the fluorescent mtensity was decreased gradually from d2 and dl because of the fusion with different mouse ODC degradation domams After 4-hour treatment with protem synthesis inhibitor cycloheximide, d2 fluorescent mtensity did not change very much, however, dl fluorescent mtensity decreased further 50% of its original mtensity The half-hfe of dl is around 4 hours M128V has fast folding and bright fluorescent mtensity, which makes it useful for number of apphcations Some fusion protems were tested such as PKC-gamma-YNFP (Ml 28V) PKC-gamma was observed to translocate from cytosol to the plasma membrane when ceUs were treated with PMA (Phorbol 12- Myπstate 13 -Acetate) D Construction and Functional Test for Humanized M128V Humanized Ml 28V was generated, and then placed mto the pEGFP-Nl backbone This vector has the same mutiple clomng sites as pEGFP-Nl Construction of Cl and pEGFP is m the process VI Characterization of drFP583 and mutants thereof A Expression m Mammalian Cells HeLa cells were transfected either with plasmid pDsRedl-Nl (vector contammg the DNA encodmg drFP583) or plasmid pEGFP-Cl (encoding EGFP from Aequorea victoria) Immediately after the transfection, cells were mixed and plated on covershps Cells were mcubated for 48 hours at 37°C then fixed m 3 7 % formaldehyde Cells were mounted m mounting medium and observed by fluorescence microscopy Images were taken from the same field of view with Chroma filter set 31001 for EGFP and filter set 31002 for drFP583 usmg a cooled CCD camera (Roper Scientific) and MetaMorph software (Umversal Imagmg) The images were pseudocolored and overlay ed Phase contrast was taken from the same field of view and overlayed B Generation of Humanized drFP583 Since mammahan expression is a very popular tool, human favored codon version is needed for better expression in mammalian cells. Humanzied drFP583 was therefore generated by changing wild type drFP583 nucleotide sequence to optimize the codons for expression of the fluorescent protein. C. Expression of Humanized drFP583 in Mammahan Cells HeLa cells were transiently co-transfected with plasmids pECFP-Nuc, pEYFP-Tub and pDsRedl- Mito (humanized drFP583). After ttansfection, cells were incubated for 48 hours at 37 °C then fixed in 3.7 % formaldehyde. CeUs were mounted in mounting medium and observed by fluorescence microscopy. Images were taken of one cell co-expressing all three fluorescent proteins with Omega filter set XF 35 for DsRedl - Mito, XF 104 for EYFP -Tub and XF 114 for ECFP-Nuc using a cooled CCD camera (Roper Scientific) and MetaMorph software (Universal Imaging). Individual images were peudocolored and overlayed to show all three signals in one image. Protein DsRedl -Mito localizes to mitochondria, EYFP-Tub localizes to the microtubular network, and ECFP-Nuc localizes to the nucleus. As a conclusion, drFP583 does emit to a low extent also in the cyan (ECFP), green (EGFP) and yellow-green (EYFP) emission channels (filter sets). High expression levels or highly concentrated protein in intracellular structures can therefore result in high signal intensities that will give some bleedthrough in the other emission wavelengths. The bleedthrough is small and should not affect multiple labeling recording in most cases. D. Mutants of Humanized drFP583 Mutants of humanized drFP583 were generated using error prone PCR technique (Clontech). Mutations occuned at amino acids 42, 71, 105, 120, 161 and 197 (numbering starting from the first Methionine). Table 7 lists the mutants that were generated and their properties. TABLE 7 Mutants of Humanized drFP583 E. Characterization and Apphcations of E5 Mutant E5 (VI 05 S197T) changes its fluorescence from green to red over time boύi in vitro and in vivo, in E. coli and in mammahan cells. Also, E5 folds faster than wild type drFP583 both in E. coli and mammahan cells. Since it allows the "two color" reporting mode for monitoring of the promoter activity, i.e., for botii active or shutdown state of the promoter, there is a separate color, serving as an indicator of that state, E5 can be used as a transcriptional reporter. Different from "one color" mode, "two color" mode has a measurable signal (color) present for both states of the process as opposed to "one color" mode (e.g. destabihzed GFP) wherein the absence of the color is an indicator of the second state. Namely, newly produced E5 protein fluoresces in green, indicating on-going promoter activity. Over time, the protein will mature, acquiring the red fluorescence. So if the promoter is no longer active, all the protein will eventually mature, resulting in the dominant red fluorescence. In case the promoter is still active both red and green fluorescence will be readily detected. Thus E5 as a "two color" reporter allows study of gene expression similar to destabihzed GFP, but with permanent "signature" of past gene activity in the cells, tissues or entire organism. For example, at the tissue level, E5 may help to distinguish the stem cells from differentiated cells. Providing the promoter is only active in the stem cells, the E5 reporter will label the stem cell population in green and red, the progenitor cells would be labeled predominantly in red, the terminally differentiated will not fluoresce (due to the titration out of protein during cell division). E5 can be used for spatial and temporal visualization of newly synthesized vs. accumulated fusion proteins. That is, E5 could function like a fusion tag. Possible apphcations envisaged at different organizational levels. At the cellular level, E5 may help to visualize and distinguish the newly synthesized proteins in various compartments such as outer membrane, microviUae, ER, Golgi, mitochondria, nuclei, various components of cellular matrix and focal adhesion complexes. At the tissue level, E5 may be helpful in visualizing newly formed vs. preexisting structures e.g. membrane junctions, components of extracellular matrix. One of the most fascinating applications of E5 seems to be in the study of the mother-daughter relationship during the cell division and migration. A wide horizon is opening in the fields of development as well as in the adult organisms to study the cell migration and differentiation. Allowing visualization of the expression "history", E5 can help to distinguishing between the mother cells where the promoter is actually active vs. the daughter cells containing the accumulated protein but not producing fresh protein anymore. It would enable the study of the cell fates during development and organ remodeling, thus distinguishing between cell migration and cell expansion or differentiation. In conclusion, E5 is basically applicable to any situation where GFP was previously used. Main advantage is that E5 can track down "the history" of promoter activity or protein localization in cells or tissues. With a better protein stability than GFP, E5 allows longer analysis window (wild type drFP583 is stable for at least 4 weeks in Xenopus, while EGFP starts to faint after two weeks). F Characterization and Apphcations of E8 Mutant E8 (N42H) has two fluorescence maximums, green and red, at all times and it folds much faster than drFP583 (Table 7) Smce it detects both green and red fluorescence simultaneously, E8 may be useful for studying processes related to blood circulation and proteins/cells traffickmg Blood absorbs the green fluorescence, thus only the red fluorescence will be visible while the protem is traffickmg m the blood Both green and red fluorescence could be detected outside the bloodstream making the whole process easy to visualize and record Momtormg both red and green fluorescence simultaneously may also help to reduce the background fluorescence problems for some tissues or cells G Generation of drFP583/dmFP592 Hybrid Usmg Shuffling Procedure Non-humanized wild type codmg region fragments from drFP583 and dmFP592 were amplified by PCR (22 cycles, 95°C, 15 sec , 68°C 1 mm 20 sec ) usmg 1 ng of corresponding bacterial expression plasmids (pQE-30 derivatives with drFP583 and dmFP592 inserts, respectively) as templates Oligonucleotides A (ACATGG ATCCAGGTCTTCCAAGAATGTTATC, SEQ ID No 23), B (TAGTACTCG AGCCAAGTTCAGCCTTA SEQ ID No 24), C (ACATGGATCCAG TTGTTC CAAGAATGTGAT, SEQ ID No 25), and D (TAGTACTCGAGGCCATTA CCGCT AATC, SEQ ID No 26) were used as primers for amplifying these fragments m a concentration of 0 2 mM The PCR products were then purified by QIAquick PCR Purification Kit (QIAGEN) Afterwards, the purified fragments drFP583 and dmFP592 (300-500 ng each) were digested with restriction endonucleases EcoRI, Hindlll and Dral (10 U each) simultaneously Reactions were performed m BamHI resttiction buffer (NEB) supplemented BSA for 3h at 37°C Total reaction volume was 30 ml Upon completion, the resulted resttiction fragments from each restriction reaction were separated by electrophoresis m agarose gels (1 5%), cut from gel and purified by QIAquick Gel Purification Kit (QIAGEN) The resulting sets of the purified resttiction fragments from both drFP583 and dmFP592 were combmed together and 50 ng of them were put mto hgation mix (IX T4 DNA ligation buffer, 400 NEB U of T4 DNA hgase) m total volume of 30 ml The ligation was performed for 3h at room temperature and stopped by heating at 70°C within 20 nun The hgation mixture was then diluted by water ten-folds, and 1 ml of the dnution was preformed for PCR reaction (20 cycles, 95°C, 15 sec 68°C 1mm 20 sec) as template Four oligonucleotides A, B, C, and D (SEQ ID Nos 58-61, respectively) were used simultaneously as primers for amplifying these fragments in a concentration of 0 1 mM each After electrophoresis m an agarose gel (1 5%), the target fragment was purified by QIAquick Gel Purification Kit (QIAGEN) and digested with resttiction endonucleases BamHI and Xhol (30-50 U each) simultaneously m BamH I restriction buffer (NEB) supplemented with BSA for 3h at 37°C After purification, the resulting fragment was cloned m pQE-30 plasmid linearized by BamHI and Sail Ligation reaction was performed m IX T4 DNA ligation buffer and 400 NEB U of T4 DNA hgase with a total volume of 20 ml for overnight at 16°C. After transformation of E. coli cells by 1/5 of the hgation volume and incubation on LB/1% agar plates which were supplemented by 100 mg/ml Ampacilin and 0.1 mM IPTG at 37°C for overnight, the resulting E. coli colonies were screened visually under fluorescent microscope using rhodamine filter set. The brightest red colonies were picked up and placed in 200 ml LB medium with 100 mg/ml of Ampacilin. At the E. coli culture was induced by IPTG (final concentration was 1 mM) and the fermentation continued for overnight. Purification of recombinant protein containing N-terminus 6xhis tag was performed using TALON metal-affinity resin according to manufacturer's protocol. H. Spectral Properties of drFP583/dmFP592 Hybrid The emission and excitation spectra for drFP583/dmFP592 hybrid protein are basically the same as for dmFP592. Table 8 lists the spectral properties of drFP583/dmFP592 hybrid protein. TABLE 8 Spectral Properties of drFP583/dmFP592 Hybrid *relative quantum yield was determined as compared to the quantum yield of A. victoria GFP. **relative brightness is extinction coefficient multiphed by quantum yield divided by the same value for A. victoria GFP. I. Humanized drFP583/dmFP592 Hybrid and Mutants drFP583/dmFP592 hybrid was humanized. Further, two mutants were generated based on the humanized drFP583/dmFP592, i.e., drFP583/dmFP592-2G and drFP583/dmFP592-Q3. drFP583/dmFP592- 2G contains two substitutions, K15Q and T217S . This mutant was derived from the humanized drFP583/dmFP592 hybrid gene by random mutagenesis using Diversity PCR Mutagenesis Kit (Clontech) according to the corresponding protocol. drFP583/dmFP592-Q3 contains three substitutions, K15Q and K83M and T217S. drFP583/dmFP592-Q3 mutant was derived from drFP583/dmFP592-2G mutant by random mutagenesis using Diversity PCR Mutagenesis Kit (Clontech) according to the conesponding protocol. drFP583/dmFP592-2G has similar brightness and folding rate as for non-humanized drFP583/dmFP592 hybrid. While drFP583/dmFP592-Q3 could be seen in E.coli cells as more dark red than parental variant, i.e., drFP583/dmFP592-2G, and the purified protein solution has purple color. drFP583/dmFP592-Q3 has the emission maximum of 616 nm and excitation maximum of 580 nm. J. Applications of Hybrid Mutants Similar to fluorescent protein drFP583 or dmFP592, drFP583/dmFP592-Q3 can be used as a tool for investigation of protein expression, ttansport and protein interactions in vivo, monitoring of promoter activity, and as a transcription reporter or fusion tag Besides, drFP583/dmFP592-Q3 can be chosen as the most convement partner to one of the existing green fluorescent protem variants m two/triple color labeling assays for simultaneous detection of expression of two or more proteins in vivo due to its sttongly red-shifted position of emission maximum and practical absence of excitation m green part of spectrum except any spectral overlappmg and background fluorescence The method of generatmg drFP583/dmFP592 hybrid can have a general utility for generating hybrid genes (1 e , genes contammg parts of different genes m various combinations) with unproved fluorescent characteristics Additionally, drFP583/dmFP592-Q3 is the first red-shifted mutant, which demonstrates that spectral- shifted mutant could be obtamed by random mutagenesis VII Characterization of asFP600 and Mutants thereof A Mutant Generation A mutant of asFP600 was generated, Mutl Compared with wild type asFP600, Mutl has the following substitutions T to A at position 70 (numbermg according to GFP) and A to S at position 148 Target substitution A148S was generated by means of site-specific mutagenesis usmg PCR with primers that earned the mutation Durmg this mutagenesis random substitution T70A was generated by introducing a wrong nucleotide m PCR The substitution T70A is not necessary for fluorescence and practically does not affect the fluorescence Table 9 lists the spectral properties of Mutl Another mutant of asFP600 was generated, havmg a substitution of the alanine at position 184 to Serme TABLE 9 Spectral Properties of the Isolated Mutl *relative brightness is extinction coefficient multiphed by quantum yield divided by the same value for A victoria GFP B Construction and Functional Analysis of Vectors Non-humanized mutant asFP600 (RNFP) DNA were amplified via PCR and reconstructed to EGFP- Nl backbone This vector (pRNFP-Nl) has the same multiple clomng sites as EGFP-Nl Functional test of the generated vector was performed by transient transfection m 293 cells 24 hours post transfection, expression of asFP600 was exammed under fluorescent microscope asFP600 showed good fluorescent mtensity, however, the expression of asFP600 concentrated at the nucleus C. Generation of Cytosal Expressed asFP600 Since the nuclear localization of asFP600 limited some of the apphcation of this protein as transcription reporter or pH sensor, cytosal expression of this protein would be needed for this purpose. A nuclear export sequence in humanized codon usage was fused to the N-terminus of asFP600, and placed into the EGFP-Nl vector, resulted in pNE-RNFP. Functional test of NE-RNFP is performed by transient ttansfect the pNE-RNFP into 293 cells. 24 hours post ttansfection, expression of NE-RNFP is examined under fluorescence microscope. Red fluorescence was observed to be distributed in the cytosol but not in the nucleus. D. Generation of Destabihzed asFP600 Vectors as Transcription Reporters Since asFP600 is very stable, it is necessary to generate destabihzed versions of asFP600 in order to observe the rapid turnover of the protein. By using the same technology for destabilized EGFP, two destabilized NE-RNFP vectors were constructed by fusing mouse ODC degredation domain to the C-terminal of NE-RNFP. The dl version of destabihzed RNFP has three E to A mutations within MODC degradation domain comparing to d2 version, therefore result in a shorter half-life of the protein to which MODC degradation domain fused. Destabihzed dlRNFP and d2RNFP were constructed in EGFP-Nl backbone. E. Functional Analysis of Destabilized asFP600 d2 version of the none-humanized asFP600 was transiently transfected into 293 cells. One day after ttansfection, CHX was added to inhibit protein synthesis. 3 hours after treatment, cells were examined under fluorescent microscope. It showed that fluorescent intensity decreased -50%. F. Construction and Functional Test for Humanized Mutl Humanized Mutl was generated. The humanized Mutl was then placed into the pEGFP-Nl backbone. This vector has the same multiple cloning sites as pEGFP-Nl. Construction of Cl and pEGFP is in the process. It is evident from the above discussion and results that the subject invention provides important new chromoprotems and fluorescent proteins and nucleic acids encoding the same, where the subject proteins and nucleic acids find use in a variety of different apphcations. As such, the subject invention represents a significant contribution to the art. All publications and patent apphcations cited in this specification are herein incorporated by reference as if each individual publication or patent apphcation were specifically and individually indicated to be incorporated by reference. The citation of any pubhcation is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such pubhcation by virtue of prior invention. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in hght of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

Claims: WHAT IS CLAIMED IS I An Anthozoa chromo- or fluorescent protem present in other than its natural environment 2 The protem according to Claim 1 , wherem said protem has an absorbance maxunum rangmg from about 300 to 700 nm 3 The protem accordmg to Claim 2, wherem said protem has an absorbance maxunum rangmg from about 350 to 650 nm 4 The protem according to Claim 3, wherem said protem has an absorbance maxunum rangmg from about 400 to 600 nm 5 The protem according to Claims 1 to 4, wherem said protem has an excitation spectrum rangmg from about 300 to 700 nm and an emission spectrum rangmg from about 400 to 800 nm 6 The protem according to Claim 5, wherem said protem has an excitation spectrum rangmg from about 350 to 650 nm and an emission spectrum rangmg from about 425 to 775 nm 7 The protem according to Claim 6, wherem said protem has an excitation spectrum rangmg from about 400 to 600 nm and an emission spectrum rangmg from about 450 to 750 nm 8 The protem according to Claims 1 to 7, wherem said protem has an ammo acid sequence substantially the same as or identical to the sequence of SEQ ID NOS 02, 04, 06, 08, 10, 12, 14, 16, 18 9 The protem according to Claim 8, wherem said protem has a sequence identity of at least about 60% with a sequence selected from the group consistmg of SEQ ID NOS 02, 04, 06, 08, 10, 12, 14, 16, 18 10 The protem according to Claim 9, wherem said protem has a sequence identity of at least about 75% with a sequence selected from the group consisting of SEQ ID NOS 02, 04, 06, 08, 10, 12, 14, 16, 18 I I A fragment of a protem according to Claims 1 to 10 12 A nucleic acid present m other than its natural environment, wherem said nucleic acid has a nucleotide sequence encoding an Anthozoa chromo- or fluorescent protem accordmg to Claims 1 to 10, or a fragment thereof according to Claim 11 13. A nucleic acid according to Claim 12, wherein said nucleic acid has a nucleic acid sequence that is substantially the same as or identical to the nucleotide sequence of SEQ ID NOS:01, 03, 05, 07, 09, 11, 13, 15, 17. 14. The nucleic acid according to Claim 13, wherein said nucleic acid has a sequence similarity of at least about 60% with a sequence selected from the group consisting of SEQ ID NOS: 01, 03, 05, 07, 09, 11, 13, 15, 17. 15. The nucleic acid according to Claim 14, wherein said nucleic acid has a sequence similarity of at least about 75% with a sequence selected from the group consisting of SEQ ID NOS: 01, 03, 05, 07, 09, 11, 13, 15, 17. 16. A fragment of the nucleic acid according to Claims 12 to 15. 17. An isolated nucleic acid or mimetic thereof that hybridizes under stringent conditions to the nucleic acid according to Claims 12 to 16 or its complementary sequence. 18. A construct comprising a vector and a nucleic acid according to Claims 12 to 17. 19. An expression cassette comprising a transcriptional initiation region functional in an expression host, a nucleic acid having a nucleotide sequence found in the nucleic acid according to Claim 12 to 17 under the transcriptional regulation of said transcriptional initiation region, and a transcriptional termination region functional in said expression host. 20. A cell, or the progeny thereof, comprising an expression cassette according to Claim 19 as part of an extrachromosomal element or integrated into the genome of a host cell as a result of introduction of said expression cassette into said host cell. 21. A method of producing a protein according to Claims 1 to 10, said method comprising: growing a cell according to Claim 20, whereby said protein is expressed; and isolating said protein substantially free of other proteins. 22. An antibody binding specifically to a protein according to Claims 1 to 10 or a fragment according to Claim 11. 23. The antibody according to Claim 22, wherein said antibody is a polyclonal antibody. 24 The antibody accordmg to Claim 22, wherem said antibody is a monoclonal antibody 25 A transgemc cell or the progeny thereof compnsmg ttansgene selected from the group consisting of a nucleic acids accordmg to any of Claims 12 to 17 26 A transgemc orgamsm capable of expressmg a protem accordmg to Claims 1 to 10 27 In an apphcation that employs a chromo- or fluorescent protem, the improvement compnsmg employmg a protem according to Claims 1 to 10 28 In an apphcation that employs a nucleic acid encodmg a chromo- or fluorescent protem, the improvement compnsmg employmg a nucleic acid according to Claims 12 to 17 29 A kit compnsmg a protem according to Claims 1 to 10 or a means for producmg the same 30 A kit compnsmg a nucleic acid according to Claims 12 to 17

Inventors: FRADKOV ARCADY FEDOROVICH, LABAS YULII ALEKSANDROVICH, LUKYANOV SERGEY ANATOLIEVICH, MATZ MIKHAIL VLADIMIROVICH, TERSKIKH ALEXEY, FRADKOV, ARCADY FEDOROVICH, LABAS, YULII ALEKSANDROVICH, LUKYANOV, SERGEY ANATOLIEVICH, MATZ, MIKHAIL VLADIMIROVICH, TERSKIKH, ALEXEY
Applicants: CLONTECH LAB INC, FRADKOV ARCADY FEDOROVICH, LABAS YULII ALEKSANDROVICH, LUKYANOV SERGEY ANATOLIEVICH, MATZ MIKHAIL VLADIMIROVICH, TERSKIKH ALEXEY, CLONTECH LABORATORIES INC., FRADKOV, ARCADY FEDOROVICH, LABAS, YULII ALEKSANDROVICH, LUKYANOV, SERGEY ANATOLIEVICH, MATZ, MIKHAIL VLADIMIROVICH, TERSKIKH, ALEXEY
Application year: 2000
Main classification: C07K14
IPC codes: A01K67, C07K14, C07K16, C12N1, C12N5, C12N15, C12P21